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Rio1 kinase is an atypical protein kinase that is essential for the proper 
maturation of the 40S subsunit during ribosome biogenesis. Ribosome biogenesis is 
linked to cell cycle progression and studies have shown that the process is 
upregulated in both normal and abnormal highly proliferative cells in order to meet 
cell demands. In an effort to regulate cell proliferation especially in abnormal 
dividing cells, the work described here takes the approach of modulating ribosome 
biogenesis by targeting Rio1 kinase. Several small molecules were tested for binding 
to afRio1 and toyocamycin, an adenosine analog, had the highest binding affinity. A 
co-crystal structure of afRio1 with toyocamycin bound was determined at 2.0Å 
revealing occupancy of toyocamycin in the ATP binding pocket. Steady state kinetic 
studies revealed that inhibition occurred via both competitive and non-competitive 
mechanisms. This analysis also revealed that Rio1 accesses multiple oligomeric states 
and autophosphorylation reduces formation of oligomers. Autophosphorylation may 
therefore modulate Rio1 enzymatic activity through regulating oligomerization. 
Additional inhibition studies revealed that afRio1 was susceptible to substrate 
inhibition at high concentrations of ATP.  
The crystal structure of human Rio1 kinase (RioK1) was also determined, 
providing the first structure of a eukaryotic Rio1 kinase. This work was 
complemented with biochemical studies that revealed RioK1 shared similar trends as 
afRio1 including affinity for toyocamycin, formation of oligomers in the presence of 
different ligands and substrate inhibition at high concentrations of ATP suggesting 
that both afRio1 and RioK1 may share the same substrate inhibition mechanism.  
 In addition to work done on Rio1 kinase, structural determination of EspB, a 
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Chapter 1: Introduction	  
 
          Protein kinases are involved in various cellular processes such as regulation of 
gene expression, DNA transcription, signal transduction, cell cycle progression and 
ribosome biogenesis (1-5). Kinases’ involvement in numerous cellular processes 
implicate them in diseases such neurodegenerative disorders, cystic fibrosis, 
HIV/AIDs and cancer (6-9). These enzymes catalyze the phosphorylation reaction 
that entails the transfer of a γ- phosphate of purine nucleotide triphosphates (ATP and 
GTP) to protein residues such as serine, threonine and tyrosine (10). Two 
phosphorylation mechanisms have been proposed; the SN2 reaction and general base 
catalysis (11, 12). SN2 reaction involves a concerted attack of a nucleophile (the 
hydroxyl group on the residues) onto the γ-phosphate of purine nucleotide 
triphosphates (Figure 1.1). This mechanism was first supported by isotopic and 
crystallographic studies of a ternary complex of Protein Kinase A (PKA) complexed 
with ATP/Mg2+ and its inhibitor, PKI (13-15). On the other hand the general base 
catalysis is supported by crystallographic studies of PKA complexed with ATP and 
Kemptide, a PKA substrate (12). It involves a conserved aspartate residue that 
functions as a catalytic base by deprotonating the hydroxyl group to promote 
nucleophilic attack on the γ- phosphate (12). The SN2 reaction is the more acceptable 
mechanism given that in general base catalysis deprotonation of the hydroxyl group 
results in a negatively charged oxygen that would cause charge repulsion with the 
negatively charged phosphates of ATP.	  
           Kinases are among the largest protein superfamilies with over 518 members 
identified in the human genome (10, 16, 17). These kinase members are classified as 
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either eukaryotic protein kinases (ePKs) or atypical protein kinases (aPKs) and they 
both contain a kinase signature that’s comprised of conserved residues required for 
kinase activity. However, aPKs are not significantly related to ePKs in sequence and 
there are more ePKs members compared to aPKs. Currently they are 40 atypical 
protein kinase members in thirteen different families including the RIO family (16, 
18).  
 
1.1 Atypical RIO Kinase Family  
           Evolutionary studies indicate a shared ancestry between ePKs and RIO kinases 
with an indication that RIO kinases predated ePKs (19, 20). The RIO family was first 
discovered through genomic studies in budding yeast in 1996 that identified the right 
open reading frame 1 (RIO1) (21). The following year, the RIO family was 
characterized based on studies of Rio1 that showed that it was a serine kinase that 
was expressed constitutively at low levels in yeast cells and had a distant sequence 
similarity with ePKs (22, 23). Since then progress has been made in this family with 
the identification of four subfamilies, bacterial Rio, Rio1, Rio2 and Rio3. In addition 
crystal structures of Rio1 and Rio2 from Archaeoglobus fulgidus that were integral in 
defining the RIO catalytic domain, have been determined. (24-26). Rio1 and Rio2 are 
present from archaea to humans whereas Rio3 is only found in multi-cellular 
eukaryotes (27, 28). These subfamilies are distinguishable by their subfamily-specific 
N-terminal domains that are found outside the RIO domain (Figure 1.3) (24, 27). 
Rio1 has two additional alpha helices (α1 and α2) on the N-terminal whereas Rio2 
has a winged-helix domain, a domain which is mostly found to participate in DNA 
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binding (Figure 1.2) (24, 26). On the other hand, the N-terminal structural feature of 
Rio3 has not yet been identified due to lack of a crystal structure. Primary sequence 
analysis of the RIO catalytic domain shows that Rio1 and Rio3 are most closely 
related in the RIO domain, consistent with the idea that Rio3 arose in metazoa from 
gene duplication of Rio1 (Figure 1.3) (27). 
 
1.2 RIO catalytic Domain. 
            RIO catalytic domain has a 3-dimensional fold consisting of an N-lobe 
composed of a β-sheet adjacent to a single α helix (αC) and a helical C-lobe (Figure 
1.4). The RIO catalytic domain has subdomains with conserved residues required for 
binding and orientation of ATP as well as transfer of the γ-phosphate to the substrate 
(24-26). These subdomains include a nucleotide binding loop (p-loop) that binds the 
phosphates on ATP; a hinge region found between the N-lobe and the C-lobe that 
binds the adenine moiety via hydrophobic and hydrogen bonding interactions; a 
catalytic loop that contains a catalytic aspartate and a conserved asparagine required 
for phosphoryl transfer; and a metal-binding loop (DFG loop) that has a conserved 
aspartate residue for positioning divalent cations (24, 29) (Figure 1.4 A-B). The RIO 
domain lacks an activation loop (APE loop) that regulates kinase activity and 
substrate binding subdomains (subdomain X and XI) that are present in the ePK 
catalytic domain. This suggests that RIO proteins bind and interact with substrates 
differently from ePKs. Another observable difference between the ePK and RIO 
catalytic domains is the difference in conformation of bound ATP, specifically the 
distance between the γ-phosphate and the catalytic aspartate. For instance in Protein 
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Kinase A, an example of ePKs, this distance is 3.8 Å compared to 5.1 Å in 
Archaeoglobus fulgidus Rio1 suggesting a possible difference in catalytic mechanism 
(24, 30). 
 
1.3 Rio1 Kinase: Background and Roles  
            Rio1 kinase is the founding member of the RIO family and based on 
autophosphorylation and phosphoamino acid analysis, this protein is classified as a 
serine kinase (24, 31). Rio1 is an essential gene in the yeast species Saccharomyces 
cerevisiae and it is required for cell cycle progression, chromosome maintenance and 
ribosome biogenesis (18, 32, 33).  During cell cycle progression Rio1 kinase is 
needed for exit from both the G1 phase and mitosis (32).  Cells depleted of Rio1 are 
enlarged and found in clusters indicative of arrest in the G1 phase and some cells 
have a single DNA mass at the bud neck as well as short spindles indicative of arrest 
at the metaphase during mitosis (32).  
            Rio1’s involvement in chromosome maintenance occurs during mitosis, where 
Rio1 is needed for chromosome stability and nuclear segregation. This is evident in 
cells depleted of Rio1 that have faulty DNA replication, incomplete DNA repair and 
defects in sister chromatid segregation (32). In addition to cell cycle progression and 
chromosome maintaince, studies in Saccharomyces cerevisiae, have identified Rio1 
kinase as a non-ribosomal protein involved in the maturation of 18S rRNA during 
ribosome biogenesis (34).  
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1.4 Ribosome Biogenesis and Rio1’s involvement. 
          A lot of progress has been made in the study of ribosomes from 1958 when 
George Palade used electron microscopy to identify the varying patterns of the 
ribosome, for which he won a nobel prize, to the current crystal structure of the 80S 
eukaryotic ribosome solved in 2010 (35-43). Ribosomes are burdened with correctly 
and efficiently producing proteins in the cell making ribosome biogenesis a highly 
complex and well-coordinated process in both prokaryotes and eukaryotes. In 
eukaryotes, ribosome biogenesis has been well studied in yeast cells where the 
process starts in the nucleolus with the synthesis of the precursors 35S and 5S pre-
rRNAs by RNA polymerase I and III respectively (44, 45). The 35S precursor forms a 
large ribonucleoprotein (RNP) complex with both ribosomal and non-ribosomal 
proteins. This complex is processed to the 60S subunit (5.8S, 25S rRNA) and the 40S 
subunit (18S rRNA) (46). The rRNA precursors are extensively modified and their 
maturation as well as assembly into ribosomal subunits involves more than 170 
proteins (45). These proteins include endo- and exonucleases, ribosomal and non-
ribosomal factors, chaperones, RNA helicases and small nucleolar ribonucleoprotein 
particles (snoRNPs) (44, 45). Some of the modifications include pseudouridylation, 
2’O-methylation and cleavage of pre-rRNAs.  A brief description of the process 
begins with pseudouridylation and 2’O-methylation of the 35S pre-rRNA. The 35S 
pre-rRNA is then cleaved at A0 and A1 sites resulting in the 32S pre-rRNA that is 
further cleaved at the A2 site producing 27SA2 and 20S pre-rRNAs (Figure 1.5) 
(44, 45). The 27SA2 undergoes further cleavages to produce mature 25S and 5.8S 
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rRNAs that are assembled in 60S subunit. The 20S pre-rRNA undergoes cleavage at 
the D-site to produce mature 18S rRNA that is assembled in the 40S subunit (Figure 
1.5). Rio1 kinase is involved in this cleavage at the D-site and cells depleted of Rio1 
have an accumulation of the 20S pre-rRNA (33, 34).  
A recent report has shown the involvement of human Rio1 (RioK1) in 
ribosome biogenesis through complex formation with human protein arginine 
methyltransferase 5 (PRMT5) (47). In this complex, RioK1 recruits nucleolin, a 
protein involved in multiple functions in ribosome biogenesis such as binding to 
nascent rRNA and providing cytoplasmic stability (48). Once nucleolin is recruited to 
the PRMT5 complex, it undergoes dimethylation that is necessary for modulating 
nucleolin’s interactions with rRNA (47).  
 
1.5 Linking Ribosome Biogenesis to Cell Proliferation. 
              Ribosome biogenesis is upregulated in both normal and abnormal 
proliferative cells. Upregulation of ribosome biogenesis is necessary for increased 
protein production and production of new ribosomes for new daughter cells. A 
characteristic feature of highly proliferating cells such as cancer cells is an enlarged 
nucleolus. The nucleolus is the compartment where rRNA processing occurs (49-51). 
This enlargement is a result of increased levels of rRNA transcription, rRNA 
processing and increased expression of ribosomal proteins (51). Therefore, there is a 
need to regulate cell proliferation, especially in abnormal dividing cells by possibly 
modulating the rate of ribosome biogenesis. This approach takes on the idea of 
targeting and inhibiting either ribosomal or non-ribosomal proteins. It has previously 
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been shown that blocking ribosome biogenesis inhibits cell proliferation but not cell 
growth. This is well illustrated in mice, where deletion of the ribosomal protein S6 in 
the liver results in reduced cell proliferation but the liver is able to grow in response 
to nutrient stimuli (52).  Bolstered by this data and further evidence that RioK1 is 
overexpressed in colon cancer cells, some of the work described in this thesis seeks to 
address the possibility of inhibiting Rio1 by carrying out both biochemical and 
crystallographic studies (53).  
 
1.6 Protein x-ray crystallography: The phase problem and the solutions.   
             Protein crystallography dates back to 1934 when J.D. Benal and Dorothy 
Crowfoot measured diffraction from hydrated pepsin crystals. The first crystal 
structure solved was the sperm whale myoglobin in the late 1950s by Max Perutz and 
Sir John Cowdey Kendrew for which they both received the Nobel Prize in chemistry 
in 1962 (54). Since then over 59,007 protein structures have been solved and 
deposited to the protein data bank (PDB). Along with the increased number of solved 
protein structures, x-ray crystallography methods have also advanced with better 
detectors and improved software for structure determination. However, one obstacle 
that crystallographers face is the phase problem that arises during data collection 
when the crystal diffracts x-ray beams that are recorded as reflections. These 
reflections are treated as complicated waves and the ultimate goal of a 
crystallographer is to obtain an electron density map that reveals the molecular shape 
of the protein. In order to obtain the electron density map, a periodic function that is  
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Equation 1: Electron density equation ρ(x,y,z). A sum of the reflections’ amplitude 
(|Fhkl|), frequencies (h,k,l) and phases (α).  
 
To solve this periodic function, the amplitudes, frequencies and phases have 
to be determined. Only two of these parameters are directly acquired during data 
collection, the amplitude that is represented by |Fhkl| and the frequencies represented 
by h, k, l, in the equation. Unfortunately the phases cannot be determined directly and 
methods for acquiring phases have been developed that include molecular 
replacement and single wavelength anomalous dispersion (SAD). Molecular 
replacement uses phases from a previously solved crystal structure as initial phases 
for the new protein.  For molecular replacement to be successful, the sequence 
identity between the new protein and the known protein, also known as the search 
model, has to be at least 30%.  Unlike molecular replacement, SAD phasing relies on 
heavy atoms to obtain phases for the new protein. The heavy atoms can be introduced 
by either soaking in ionic solutions or as modified amino acids during expression. 
The most common heavy atom is selenium and it is incorporated into the protein 
during expression in media that has methionine replaced with selenomethionine (Se-





| Fhkl | e∑∑∑ −2 πi (hx+ ky+ lz−α )
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break Friedel’s law that requires intensities of symmetry related reflections to be 
equal i.e. Ihkl=I(-h,-k,-l). Once data is collected, the heavy atoms are located by Patterson 
maps and the initial phases are calculated and then improved by density modification 
(55-57). Both phasing methods have been used in the work that will be described in 
chapter 2, 4 and chapter 6. 
 
1.7 Objectives  
            The ultimate goal is to regulate cell proliferation by possibly modulating the 
rate of ribosome biogenesis. Towards this ultimate goal, the focus of my research was 
to target the non-ribosomal protein, Rio1 by asking the following questions:          
 
1. What and where do we begin the search for potential Rio1 inhibitors that 
will aid in designing more specific inhibitors? 
2. If Rio1 potential inhibitors do exist and the mode of inhibition? 
3. Since initial studies will be carried out with Archaeoglobus fulgidus Rio1 
(afRio1), are the properties determined conserved in and applicable to 
eukaryotic Rio1 kinase? 
4. And finally, what is the structure of eukaryotic Rio1 and how does it 
compare to the archaeal structure?  
 
To address these questions, I solved the crystal structure of Archaeoglobus 
fulgidus Rio1 (afRio1) with a potential inhibitor bound. I will describe this complex 
in chapter 2. In chapter 3, I will describe as well as characterize the mode of 
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inhibition by examining the steady state kinetics and in chapter 4, I will describe the 
work that went towards determining the structure of the human Rio1 (RioK1) and 
relevant biological studies. Chapter 5 will focus on functional and mutational studies 
of afRio1.  
 
1.8 Additional work: EspB 
               In addition to my main project, I took on another project that entailed 
structural determination of EspB, a protein that is involved in the virulence of  
Mycobacterium tuberculosis (MtB). This structure was integral to my protein 
crystallography experience. Expression, purification and structural determination will 






































































Figure 1.2:	  Crystal Structures of Rio1 and Rio2 from Archaeoglobus fulgidus. 
A.Rio1with the additional alpha helices (α1 and α2) in magenta. B. Rio2 with the 
winged helix domain (wHTH) in magenta. In both structures the Rio domain starts at 





















Figure 1.3: Schematic of primary structure of Rio kinases. Adapted from 
LaRonde-LeBlanc (27). Primary sequence of Rio1, Rio2 and Rio3 showing the 
different N terminal domain and the sequence variations in the RIO domain that’s in 
yellow in Rio1 and Rio3 and orange in Rio2. Rio1 and Rio3 have similar conserved 












































Figure 1.4: RIO catalytic domain. A. Simple schematic of the Rio domain. B. 
Archaeal Rio1 (afRio1) structure (PDB ID: IZTF) with the RIO domain labeled; p is 













Figure 1.5: Ribosome Biogenesis. Simple schematic of ribosome biogenesis starting 
with large transcript 35S pre-rRNA that undergoes several modifications and 
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Chapter 2: Structure Determination of Toyocamycin Bound to Archaeoglobus 
fulgidus Rio1 Kinase (afRio1).   
2.1 Introduction. 
             In an effort to provide a means of modulating the rate of ribosome biogenesis 
with the ultimate goal of regulating cell proliferation, we decided to target Rio1, as it 
is involved in the maturation of 18S rRNA (34). The first step was to screen and 
identify small molecules that bind to afRio1 with a higher affinity than the native 
ligand, ATP/Mg2+, followed by co-crystallization studies in order to characterize the 
interactions. 
 A previously solved crystal structure of afRio1 with ATP bound revealed an 
accessible pocket in the ATP binding site where N7 of the adenine moiety is 
positioned (Figure 2.2) (24). Based on this structure three adenosine analogs, 
toyocamycin and sangivamycin and 7-methylinosine were screened for binding to 
afRio1. Toyocamycin has a carbon and a cyano group at the N7 position whereas 
sangivamycin has a carbon and an amide group at the same position (Figure 2.3). 7-
methylinosine has a methyl group at the N7 position and a hydrogen bond acceptor (a 
carbonyl group) at the C6 position that is not optimal for binding to afRio1, as is 
evident in previously solved crystal structures of afRio1 with bound ATP, ADP and 
adenosine bound (Figure 2.3) (24). In these structures the N6 position has a hydrogen 
donor (an amine group) that hydrogen bonds with the peptidyl carbonyl of Glu 148 
(24). In order to determine the affinity of these small molecules for afRio1, a 
thermofluor assay was carried out. In this assay, the protein is slowly heated up and 
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as the protein unfolds the inner hydrophobic core residues are exposed, allowing for 
hydrophobic fluorescent dyes to bind (Figure 2.4) (58). A change in fluorescent 
intensity is monitored as temperature increases and the melting temperature (Tm) is 
determined as the inflection point of the melting curve. Thermofluor assays monitor 
the shift in Tm by comparing the Tm of unbound protein, the control, to the Tm of 
protein bound to a ligand. A positive shift in Tm is indicative of strong binding and 
stabilization whereas a negative shift in Tm is indicative of destabilization of the 
protein by the ligand. 
Toyocamycin was identified as a tight-binding small molecule. This chapter 
will describe the journey from expression and purification of afRio1 to structural 
determination of toyocamycin bound to afRio1 as an initial step to designing Rio1-
specific inhibitors. 
 
2.2 Toyocamycin background 
             Toyocamycin, also known as 7-cyano-7-deazaadenosine, was first isolated in 
1956 from Streptomyces Toyocaensis, a gram-positive bacteria (59, 60). 
Toyocamycin was discovered as a pyrrolopyrimidine antiobiotic and later identified 
as an antitumor agent that can also serve as a precursor to other antitumor agents such 
as sangivamycin (Figure 2.6) (61). Studies as early as 1968 showed toyocamycin 
suppressed the formation of 28S and 18S rRNA, the mature mammalian rRNAs in the 
large and small subunit respectively (62). These studies were carried out in several 
cancer cell lines including HeLa cells, colon carcinoma cells and chick embryo cells 
infected with MC29 avian Leukosis virus (63-65).  Other studies investigating the 
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effect of low concentrations of toyocamycin on normal mammalian cells showed 
interference with the maturations of precursors ranging from 45S to 32S pre-RNAs 
(66). These precursors accumulated in the nucleoli, the compartment where rRNA 
processing begins, resulting in the lack of formation of 28S and 18S rRNA. In 
addition to inhibiting rRNA processing, toyocamycin has been shown to inhibit 
several kinases including phosphatidylinositol kinase, rhodopsin kinase and 
adenosine kinase from Mycobacterium tuberculosis (67-70). In order to test the 
binding affinity of toyocamycin to afRio1 and characterize the binding interaction the 
following experimental procedures were carried out.  
 
2.3 Experimental Procedures:  
2.3a Expression of afRio1. 
AfRio1 expression vector (cloned by my advisor, Dr. LeBlanc) with a T7 
promoter, N-terminal 6X histidine tag, Tobacco Etch Virus (TEV) was transformed 
into Rosetta DE3 E.coli cells (Novagen). These cells have tRNAs for rare codons 
(AUA, AGG, AGA, CUA, CCC, CGG, and GGA) and a pLysS plasmid that produces 
lysozyme to suppress basal expression from T7 promoter. The cells were plated on 
Lysogeny Broth (LB) Agar plates containing 100 µg/mL ampicillin and 34 µg/mL 
chloramphenicol and incubated at 37°C for 16 hours. Choice of antibiotics was based 
on ampicillin resistance provided by the expression vector and maintenance of pLysS 
plamid that requires chloramphenicol. A single colony was inoculated in 40 mL of 
LB media containing 34 µg/mL chloramphenicol and 100 µg/mL carbenicilin, an 
analog of ampicillin that is more resistance to degradation. This LB media was 
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incubated overnight at 37°C while shaking at 250 rpm. The following day, 40 mL of 
overnight culture was added to 4L of LB media containing 100 µg/mL ampicillin and 
34 µg/mL chloramphenicol and incubated at 37°C while shaking at 250 rpm. When 
the OD600 reached 0.6-0.8, within the mid-log phase, these cells were induced with 1 
mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and expression proceeded at 
20°C for 18 hours. The cells were centrifuged at 6,000 rpm and 4°C for 30 minutes 
using a Sorvall centrifuge (Dupont) with a SLC 4000 rotor. The bacterial pellet was 
stored at -80°C. 
 
2.3b Purification of afRio1 
              The frozen bacterial cell pellet was resuspended in lysis buffer containing  
50 mM Tris pH 8.0, 200 mM NaCl, 0.2% β-mercaptoethanol, 0.1 mg/mL DNase1 
(Roche) and 0.3X Bugbuster (Novagen) and gently stirred on ice for 30 minutes. The 
lysate was transferred to pre-cooled centrifuge tubes that were placed in a 75°C 
waterbath for 15 minutes to denature E.coli proteins and immediately centrifuged at 
4°C and 15,000 rpm for 20 minutes using a Beckman Coulter ultracentifuge with a  
45 Ti rotor. The supernatant was filtered and loaded onto a pre-equilibrated 5 mL 
HisTrapHP column (GE healthcare) attached to a Fast Protein Liquid 
Chromatography (FPLC) system at a flowrate of 2.5 mL/min. The column was 
washed with 10 column volumes of lysis buffer to remove any unbound protein. 
Bound afRio1 protein was subjected to an imidazole gradient of 100 mM to 1 M and 
afRio1 eluted between 200 mM to 300 mM imidazole. Partially purified fractions 
were pooled together and transferred to a dialysis membrane to which 1 mg/mL of 
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Tobacco Etch Virus (TEV) protease was added to cleave the histidine tag. AfRio1 
was dialyzed overnight at 4°C into 50 mM Tris pH 8.0, 200 mM NaCl, 0.2% β-
mercaptoethanol.  After cleavage the protein was loaded onto a pre-equilibrated 5 mL 
HisTrapHP column (GE healthcare) and washed with lysis buffer. Cleaved protein 
eluted with the lysis buffer and was further purified by size exclusion 
chromatography using a Superdex200 column (GE healthcare) that was pre-
equilibrated in 10 mM Tris pH 8.0, 10 mM NaCl and 0.2% β-mercaptoethanol. All 
purification steps were monitored by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) for purity (Figure 2.1). 
 
2.3c Thermofluor Assay  
  Purified afRio1 (1.0 mg/mL) was incubated at 25°C for 30 minutes with  
1 mM toyocamycin, sangivamycin, 7-methylinosine and ATP/Mg2+ in a buffer 
containing 50 mM Tris pH 8.0, 75 mM NaCl and 2 mM MgCl2. The control reaction 
was afRio1 with no ligand added. After incubation, Sypro-Orange™ fluorescent dye 
(Sigma-Aldrich) was added to the reactions and heated from 30°C to 98°C at a rate of 
0.2°C per second using Bio-Rad Mini-Opticon thermal cycler. Measurements were 
done in triplicates and the Tm was determined as the inflection point of the melting 
curve. The change in Tm was calculated as the difference between the Tm of bound 
afRio1 and Tm of unbound afRio1. The Tm of unbound afRio1 was 76°C ±0.4°C 
whereas in the presence of toyocamycin a significant shift was observed with a Tm of 
88°C ±0.1°C, corresponding to a 12°C shift. In the presence of ATP/Mg2+ or 
sangivamycin the Tm was 82°C ±1.2°C and 82°C ±1.0°C respectively, a 6°C shift for 
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both molecules (Figure 2.5). In the case of 7-methylinosine the Tm was 79°C ± 0.2 °C 
having the least shift in Tm of only 3°C (Figure 2.5). These results revealed that 
toyocamycin had the most significant shift and therefore was the most stabilizing 
small molecule bound to afRio1. In order to characterize the interaction between 
afRio1 and toyocamycin, a co-crystallization experiment was carried out. 
 
2.3d Co-crystallization of afRio1 with toyocamycin.  
Purified afRio1 (21 mg/mL) was incubated with 2 mM toyocamycin at room 
temperature for one hour allow for maximum binding in a buffer containing 10 mM 
Tris pH 8.0, 10 mM NaCl and 0.2% β-mercaptoethanol. This was followed by initial 
screening of crystals with commercially available screen matrices; Index (Hampton), 
Cyros (Qiagen), PEGs suite (Qiagen), Wizard I, II and III (Emerald Biosystems) in 
96-well plates. The initial screens were setup using the Phoenix Liquid Handing 
system (Art Robbins) in three different protein to well solution ratios (1:2, 1:1, 2:1) 
using the sitting drop method.  In this method, a drop of protein and well solutions 
(precipitants, salts and/or buffers) sit in a depression and equilibration occurs by 
vapor diffusion. The 96-well plates were incubated at 20°C and afrio1-toyocamycin 
crystals were observed after seven days in PEGs Suite screen (Figure 2.7). These 
crystals grew in a 1:2 protein to well solution ratio in 0.2 M Mg(COO)2, 20% PEG 
3350, pH of 8.0. The crystals were optimized by varying the both the salt 
concentration, Mg(COO)2, from 0.15 M to 0.3 M and the precipitant, PEG 3350, from 
14% to 32%. Optimization was done using the hanging drop method in 24-well plates 
and incubated at 20°C. This method entails having a drop of protein and well solution 
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mixture placed on a glass slide or seal that covers a well containing a solution of 
buffers, salts and precipitants. The drop “hangs” over the well and equilibration 
occurs via vapor diffusion.    
             Optimized crystals were observed after a week. Several of these crystals were 
flash frozen in their respective well solution and 20% (v/v) glycerol as a cryo-
protectant to reduce radiation damage and prevent ice formation during data 
collection. The crystals were shipped to Argonne National Lab where data collection 
and processing was performed at NE-CAT beamline.  
 
2.3e AfRio1-toyocamycin complex: Data collection, processing and refinement.  
            Data was collected at 100K at the NE-CAT beamline at Advanced Photon 
Source (APS), Argonne, IL, USA. The best diffraction was to 2.0 Å resolution and 
data was indexed, integrated and scaled using HKL2000 package program (71). The 
best diffracting crystal belonged to P21	  space group and the unit cell dimensions were 
a= 52.81Å, b= 72.61Å, c= 60.56Å and α= 90.000, β= 90.170, γ= 90.000. The overall 
redundancy was 4.0 with 97.7% data completion and an overall Rsymm of 6.9% (Table 
2.1). These three parameters were used to determine the quality of data collected. The 
redundancy is the average number of independent measurements of each reflection in 
a data set and an average value above 3.0 is generally acceptable. The Rsymm, which is 
also referred to, as Rlinear is the measure of agreement among independent 
measurements of symmetry-related reflections in a data set and a value below 18% is 
acceptable. 
 Molecular replacement was used to solve afRio1-toyocamycin structure and a 
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previously solved crystal structure of afRio1 (PDB ID: IZTF) was used as a search 
model to phase afRio1-toyocamycin. Molecular replacement was carried out using 
MOLREP as part of CCP4i and the model was subjected to multiple rounds of model 
building in COOT and several rounds of refinement using PHENIX and REFMAC5 
that is part of CCP4i (72-77). Waters were added to the structure using PHENIX and 
the final model had a Rwork/Rfree of 21.6/25.5 (Table 2.2). The completely refined 
crystal structure contained two molecules of afRio1-toyocamycin complex per 
asymmetric unit (ASU) (Figure 2.8). This structure has been deposited to the Protein 
Data Bank (PDB ID: 3REA). 
 
2.4 Results  
2.4a Overall structure of afRio1-toyocamycin complex. 
             The overall structure of afRio1-toyocamycin complex consists of an N-lobe 
that has a α-helical region (α1, α2 and αR) as well as a twisted β sheet that contains 
the nucleotide binding loop (p-loop) and an α-helical C-lobe that has the catalytic and 
metal binding loops (Figure 2.8). This overall structure is consistent with the general 
features of kinases that contain an N-terminal comprised of a twisted β-sheet and an 
α-helical C-terminal (10, 24). The N-lobe and C-lobe are connected by a hinge region 
that buries the 7-cyano-7-deazaadenine ring of toyocamycin. This region buries the 
adenine ring of ATP in the afRio1-ATP complex (24).  
            AfRio1 kinase has a flexible loop consisting of residues 83 to 111 that house 
the autophosphorylation site, serine 108 (24). No electron density was observed for 
part of this flexible loop in the afRio1-toyocamycin complex; Chain A and B lack 
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density for residues 86-89 and 86-92 respectively. This is similar to the structure of 
ATP/Mg2+ bound to afRio1 for which no electron density is observed for residues 85-
91 (24). The RMSD between the two molecules of afRio1-toyocamycin in the 
asymmetric unit is 0.024 Å2 for 240 residues. This structure provides the first 
structural information linking toyocamycin to a ribosomal processing factor.   
 
2.4b Interactions of toyocamycin bound to afRio1. 
             To generate a difference electron density map (Fo-Fc) to confirm the 
presence of toyocamycin, the afRio1-toyocamycin complex was refined in the 
absence of any ligand and the resulting structure factors and phases were used to 
generate the map. This revealed electron density for toyocamycin in the ATP binding 
site (Figure 2.9A). Toyocamycin is buried in a pocket that features hydrophobic 
contact with Val 63, Ile 55 and Ala 78 from the N-lobe, Pro 156, Met 147, Phe 149 
and Ile 150 from the hinge, and Met 203 and Ile 211 from the C-lobe (Figure 2.9A). 
In addition, toyocamycin participates in ten hydrogen bond interactions. There is one 
direct interaction from the peptidyl carbonyl oxygen of Glu 148 to the amine group at 
N6 and another interaction from the indole nitrogen N1, to the peptidyl amine group 
of Ile 150 (Figure 2.9B). These interactions are observed in the afRio1-ATP complex 
(24). A hydrogen bond is seen between the 7-cyano group to a water molecule 
contacting the carbonyl side chain of Glu 120 and peptidyl amine group of Asp 212 
(Figure 2.9B). This water molecule is seen in all available structures of afRio1 and in 
the afRio1-ATP complex this water mediates a hydrogen bond between Glu 120 and 
the γ-phosphate (24). The cyano group present in toyocamycin fits well in the 
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available pocket near the N7 position and hydrogen bonding to afRio1 via Glu 120, 
providing efficient binding to the protein. The ribose 3’ OH group participates in two 
water-mediated hydrogen bond interactions; one with the side chain of Glu 162 and 
another water-mediated hydrogen bond with the peptidyl carbonyl oxygen of Tyr 200, 
an interaction not observed in the afRio1-ATP complex (Figure 2.9B). The ribose 2’ 
OH group participates in a water-mediated hydrogen bond with the peptidyl carbonyl 
oxygens of Ile 55 and Ala 157, these interactions are not observed in the afRio1-ATP 
complex. The 5’ OH has a direct hydrogen bond with Asp 212 as well as a water-
mediated hydrogen bond with the peptidyl carbonyl oxygen of Tyr 200 (Figure 2.9B). 
In the afRio1-ATP complex the Asp 212 participates in one direct hydrogen bond to 
the γ-phosphate and two Mn2+-coordinated interactions with the α- and β-phosphates 
of ATP (24). Despite the lack of the triphosphate moiety, toyocamycin is able to 
make a direct hydrogen bond with the metal binding residue, Asp 212. 
 
2.5 Discussion  
Despite the absence of the triphosphate moiety in toyocamycin and therefore 
the disruption of hydrogen and metal mediating interactions between the phosphates 
and afRio1, toyocamycin binds to afRio1 with a higher affinity than the native ligand, 
ATP/Mg2+. In addition afRio1 shares eleven hydrogen bonds with ATP whereas 
toyocamycin has only ten hydrogen bonds to afRio1, which is equivalent to about 
0.5-1.5 kcal/mol loss in energy for the toyocamycin complex. 7-methylinosine, on the 
other hand, showed the least stabilization as expected due to the absence of a 
hydrogen donor at C6 position necessary for optimal binding to afRio1. In addition, 
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repulsion between the carbonyl groups at the C6 position and the peptide bond of Glu 
148 could be a contributing factor to the weaker binding observed with 7-
methylinosine since this distance is about 3.1 Å.  
In an effort to characterize the interactions of afRio1 and toyocamycin, we 
present a complex structure that also serves as the first structure of toyocamycin 
bound to a ribosome-processing factor, Rio1. Previous studies have indicated 
toyocamycin inhibits the maturation of 18S rRNA but there are no reports in literature 
that identify a binding target for toyocamycin during ribosome biogenesis. This 
crystal structure and the high binding affinity of toyocamycin to afRio1 provides a 
potential tool that can be used to identify Rio1 substrates which have yet to be 
determined. There are several reports on the use of radiolabeled ATP analogs such as 
N6-benzyl ATP as a tool for identifying specific kinase substrates (78). The use of 
ATP analogs promotes specificity for the kinase to be studied since other kinase are 
not likely to accept the analog (78). Using the same approach, toyocamycin 5’-
triphosphate [γ-32P] can be introduced to cellular extracts from a system that has 
overexpressed Rio1 kinase. Proteins that are radiolabeled can be identified by mass 
spectrometry methods. This approach ensures that the overexpressed Rio1 is 
responsible for the transfer of γ-32 phosphate to the substrate and specificity of 
toyocamycin for Rio1 limits to some extent the possibility that other kinases are 
responsible for phosphorylation. The use of radiolabeled ATP analogs has been 
successful in many systems including in the identification of v-Src. ERK2 and CDK1 
substrates (78-80). Some drawbacks of this approach in our system include the 
possibility of toyocamycin 5’-triphosphate binding to other kinases in the cellular 
	   27	  
extract, not knowing the binding affinity of toyocamycin-5’triphophate for Rio1 and 
whether toyocamycin-5’triphophate has a higher affinity than ATP. The assumption 
is that toyocamyin binds to afRio1 with a high affinity, which does not necessarily 
mean that the triphosphate version would have the same binding affinity.  
An alternative approach of using toyocamycin as a tool to identify substrates 
is based on a recent report that identified the translational elongation factor EEF1D as 
a substrate for casein kinase 2 (81). This functional proteomic strategy would require 
treating cells with toyocamyin in the presence of ATP [γ-32P] and identifying 
proteins with diminished phosphorylation by employing 2-D electrophoresis and 
mass spectrometry. Proteins with diminished phosphorylation can be determined by 
comparing the 2-D gel results to those of a control reaction (cells that don’t have 
toyocamycin present). In order to validate identified proteins as direct substrates of 
Rio1, several approaches can be employed including: a) immuno-kinase assays that 
would require tagging the substrate and using antibodies to immuno-precipitate the 
substrate from cellular extracts followed by kinase reactions using Rio1, b) 
knockdown studies of Rio1 followed by determination of diminished phosphorylation 
of the substrates, c) designing inhibitor resistant mutants of Rio1 to evaluate the 




This chapter identifies toyocamycin as a small molecule that binds to afRio1 
in the ATP binding pocket and with a higher affinity than ATP. This provides the first 
	   28	  
crystal structure of toyocamycin bound to a ribosome processing factor and a tool for 
identifying Rio1 substrates by employing strategies presented in the discussion. The 
next focus in this project was to determine whether toyocamycin inhibits the activity 




























	   	  
	  
	  























Figure 2.1: Preparative gels of afRio1 purification. Expected molecular weight is 
30.09 kDa. Lane M in all gels is the protein ladder A. Gel after first HisTrap column 
purification, lane 1 and 2 are fractions that eluted with 10mM imidazole. Lane U is 
uninduced sample and Lane L is the lysate sample. B. Gel after the second HisTrap 
column purification, lane 1 is before histidine tag cleavage and lane 2 is after 
cleavage. C. Gel after size exclusion chromatography.   
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Figure 2.2: AfRio1-ATP active site. AfRio1-ATP complex showing an accessible 
pocket around the N7 position of the adenine moiety. The closest residue to N7 is 
6.96 Å away as shown by the red dashed line. Black dashed lines are hydrogen bonds 

















Figure 2.3: Small molecules. Chemical structure of small molecules tested for 





































Figure 2.4: Thermofluor assay. A. Schematic showing the concept behind 
Thermofluor assay concept. B. Graph showing melting curves (red and black) 
generated after a thermofluor assay. A shift in melting temperature is observed with a 











































Figure 2.5: Thermofluor assay data. A. Melting curves of the small molecules 
tested. This is a representation of one replicate measurement. B. Graph showing 
change in melting temperature (Tm). Toyocamycin has the most change in Tm with a 































Figure 2.6: Chemical conversion of toyocamycin to sangivamycin. The reaction 























































Figure 2.7: Crystals of afRio1-toyocamycin complex. A. Crystals of toyocamycin 
bound to afRio1 before optimization. B. Crystals of toyocamycin bound to 
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     Shell       Average Redundancy Per Shell
  Lower Upper      
  limit limit
  40.00  5.42             4.0
   5.42  4.31             3.8
   4.31  3.76             3.9
   3.76  3.42             3.9
   3.42  3.17             3.9
   3.17  2.99             4.0
   2.99  2.84             4.0
   2.84  2.71             4.1
   2.71  2.61             4.1
   2.61  2.52             4.1
   2.52  2.44             4.1
   2.44  2.37             4.1
   2.37  2.31             4.1
   2.31  2.25             4.1
   2.25  2.20             4.1
   2.20  2.15             4.1
   2.15  2.11             4.1
   2.11  2.07             4.1
   2.07  2.03             4.1
   2.03  2.00             3.9
  All hkl                 4.0
     Shell            I/Sigma in resolution shells:
  Lower Upper      % of of reflections with I / Sigma less than
  limit limit     0     1     2     3     5    10    20   >20  total
  40.00  5.42   0.7   0.9   1.1   1.3   1.7   2.6  22.0  76.7   98.6
   5.42  4.31   0.1   0.1   0.2   0.4   0.8   1.8  27.0  71.6   98.6
   4.31  3.76   0.1   0.3   0.3   0.3   0.6   2.4  46.1  52.2   98.3
   3.76  3.42   0.1   0.1   0.2   0.4   0.9   3.0  56.0  42.8   98.7
   3.42  3.17   0.1   0.1   0.4   1.0   2.1   7.9  70.1  28.1   98.2
   3.17  2.99   0.3   0.4   0.8   1.8   3.3  10.0  76.7  22.2   98.8
   2.99  2.84   0.1   0.4   0.6   1.7   4.0  14.6  70.8  27.0   97.8
   2.84  2.71   0.3   0.7   1.6   3.3   6.1  18.6  78.0  20.5   98.4
   2.71  2.61   0.2   1.0   2.3   4.3   9.0  27.2  76.2  22.0   98.2
   2.61  2.52   0.3   1.2   3.3   5.2  11.5  31.5  82.8  14.9   97.7
   2.52  2.44   0.6   1.8   4.6   8.3  16.1  41.9  81.8  16.1   97.8
   2.44  2.37   0.4   1.7   5.2   9.1  19.2  45.5  84.5  12.7   97.2
   2.37  2.31   1.2   2.1   5.7  10.5  20.8  48.5  84.9  12.5   97.4
   2.31  2.25   0.8   3.0   8.7  15.2  27.7  56.4  87.2   9.7   96.9
   2.25  2.20   1.4   3.7   8.3  15.9  29.3  59.0  88.1   9.2   97.2
   2.20  2.15   1.6   5.4  11.9  19.5  35.4  65.9  90.2   6.8   97.0
   2.15  2.11   1.9   5.8  13.5  23.2  42.8  72.2  92.7   4.7   97.3
   2.11  2.07   2.3   8.1  18.9  28.6  46.3  77.4  93.3   3.3   96.6
   2.07  2.03   2.9   9.9  21.3  35.5  54.5  80.9  94.5   2.2   96.7
   2.03  2.00   3.0  11.9  24.7  38.1  59.8  84.1  94.1   2.0   96.1
 All hkl        0.9   2.9   6.6  11.1  19.5  37.4  74.7  23.0   97.7
 Shell Lower Upper Average      Average     Norm. Linear Square
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac
      40.00   5.42   559.5    24.0     7.1  0.737  0.042  0.046
       5.42   4.31   601.9    27.2     9.0  0.836  0.046  0.052
       4.31   3.76   494.6    24.8     8.0  0.790  0.050  0.057
       3.76   3.42   349.1    18.1     6.8  0.914  0.056  0.064
       3.42   3.17   223.7    12.1     5.3  1.071  0.066  0.069
       3.17   2.99   162.3     9.0     4.3  1.159  0.072  0.072
       2.99   2.84   119.5     6.5     3.9  1.329  0.081  0.082
       2.84   2.71    98.3     5.6     3.5  1.318  0.086  0.082
       2.71   2.61    73.0     4.3     3.2  1.466  0.099  0.093
       2.61   2.52    63.1     4.1     3.2  1.471  0.112  0.107
       2.52   2.44    56.7     3.8     3.2  1.483  0.118  0.104
       2.44   2.37    52.0     3.8     3.2  1.423  0.125  0.110
       2.37   2.31    48.4     3.7     3.4  1.425  0.133  0.122
       2.31   2.25    42.7     3.7     3.4  1.403  0.150  0.126
       2.25   2.20    41.0     3.7     3.4  1.409  0.157  0.139
       2.20   2.15    34.0     3.6     3.4  1.312  0.179  0.164
       2.15   2.11    30.7     3.7     3.5  1.235  0.200  0.177
       2.11   2.07    25.5     3.6     3.5  1.152  0.224  0.195
       2.07   2.03    22.0     3.6     3.5  1.089  0.252  0.208
       2.03   2.00    20.2     3.7     3.7  1.085  0.282  0.243
  All reflections    158.5     8.7     4.5  1.209  0.069  0.057
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Table 2.2: Data Collection and Refinement statistics 
 
 
PDB ID: 3REA 
 
 
Toyocamycin bound afRio1 
 
Data collection  
     Space group P21 
     Cell dimensions  
           a, b, c (Å) 52.814, 72.607, 60.561 
           α, β, γ (°) 90, 90.172, 90 
     Molecules/Asym. unit   2 
      Wavelength (Å) 0.97919 
     Resolution (Å) 40-2.00 
     Rsym (last shell)  0.069 (0.282) 
     I/σI 18.2 (5.5) 
     Completeness (%) 97.7 (96.1) 




     Resolution (Å) 34.9-2.00 
     Rwork/Rfree (%) 21.6/25.5 
      Residues                c 503 
           Waters 173 
     Mean B-factors (Å)2   
    Residues /backbone 
 33.98/31.36 
     RMS deviations  
           Bond lengths (Å) 0.008 
           Bond angles (°) 1.157 
     Ramachandran plot  
           Favored  95.74% 
        Additional Allowed  4.26% 
           Disallowed    0.0% 
 













Figure 2.8: AfRio1-toyocamycin overall structure with two molecules per 
asymmetric unit. Toyocamycin is labeled as TOYO, the N-lobe is colored green and 
the C-lobe is red in both molecules.                    .                                        



































Figure 2.9: Toyocamycin binding site. A. Fo-Fc map at 2.5 σ showing electron 
density of toyocamycin in the ATP binding pocket. Residues involved in hydrophobic 
interactions with toyocamycin are labeled. B. Hydrogen bond interactions in afRio1-
toyocamycin complex. Black dashed lines represent hydrogen bonds and red spheres 
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Chapter 3: Inhibition Studies and Oligomeric State Characterizations of 
Archaeoglobus fulgidus Rio1 (afRio1). 
 
3.1 Overview 
The discovery that toyocamycin binds to afRio1 with a higher affinity and 
stabilizes afRio1 more than ATP necessitated inhibition studies in order to determine 
whether toyocamycin was merely binding to afRio1 or causing inhibition. The first 
step was to determine the steady state kinetic parameters (Km and Vmax) of afRio1 for 
ATP, followed by characterization of the inhibition of afRio1’s phosphorylation 
activity by toyocamycin. The crystal structure of afRio1-toyocamycin complex 
showed binding of toyocamycin to the ATP binding site leading to the hypothesis that 
toyocamycin was a competitive inhibitor. After analysis of kinetic parameters, a 
different type of inhibition model was used to characterize the mode of inhibition. 
This inhibition model required oligomeric state analysis by sedimentation equilibrium 
experiments as will be described in this chapter. In addition, mutational studies were 
carried out to determine the importance of a conserved residue, Tyr 200 that is 
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3.2 Experimental Procedures: 
3.2 a Steady State Kinetics studies 
           In order to determine the kinetic parameters (Km and Vmax ) of afRio1 for ATP, 
0.5 µg of purified afRio1 and 10 µg of myelin basic protein (MBP), a general kinase 
substrate that is phosphorylated by afRio1, was added to a 30 µl reaction volume in a 
buffer containing 50 mM Tris pH 8.0, 50 mM NaCl, 2 mM MgCl2 and 0.2% β-
mercaptoethanol. In order to monitor the phosphorylation activity, γ-32P labeled ATP 
was used and the amount added varied from 1.0 x10-6 M to 7.9 x10-9 M. Each reaction 
was incubated at 37°C and stopped at specific time points (0, 1, 2, 4, 6, 8, 10, 15, 20, 
30 and 40 minutes) by adding 8 µl of sodium dodecyl sulfate (SDS) loading dye and 
heating the reaction at 95°C for 5 minutes in order to denature the protein. All 
reactions were carried out in triplicates and the reaction mixtures were separated by 
running NuPAGE®4-12% Bis-Tris denaturing gels (Invitrogen) at 200V for 30 
minutes. The gels were dried, exposed onto a phosphoimager screen for 15 hours and 
quantified using ImageQuant software (Molecular Dimensions) to determine moles of 
γ-32phosphate that were incorporated into MBP. After quantifying, further analysis 
was carried out using GraphPad Prism. Initial velocity (Vo) was determined by fitting 
raw data to a linear regression plot of moles of γ-32 phosphate incorporated as a 
function of time in minutes (Figure 3.1). A plot of Vo as a function of ATP 
concentration [S] was fit to a nonlinear regression curve using the Michaelis-Menten 
equation, Vo = (Vmax [S])/(Km + [S]) and from this plot the Vmax and Km were 
determined (Figure 3.2). The same protocol was carried out for inhibition studies with 
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the addition of toyocamycin to the reaction mixtures at three different concentrations, 
20 nM, 40 nM and 60 nM. The concentrations of toyocamycin used in these 
experiments were based on the dissociation constant (Kd) that had previously been 
determined by fluorescence to be 40 nM. The two concentrations at 60 nM and 20 nM 
are simply above and below the Kd. 
 
3.2b Substrate inhibition by high concentrations of ATP 
Inhibition studies also showed that afRio1 phosphorylation activity is 
inhibited by high concentrations of ATP. In an effort to determine a range of ATP 
concentrations to use in the inhibition studies, an experiment was carried out that 
varied the range of γ-32P labeled ATP concentrations between 1.0 x 10-4 M and  
1.0 x 10-8 M. In this experiment, 0.5 µg of purified afRio1 and 10 µg of MBP were 
added to a 30 µl reaction volume in a buffer containing 50 mM Tris pH 8.0, 50 mM 
NaCl, 2 mM MgCl2 and 0.2% β-mercaptoethanol. The reactions were incubated at 
37°C for 45 minutes and the components were separated by running a gel that was 
dried and exposed on a phosphoimager. Moles of γ-32phosphate incorporated into 
MBP were quantified using ImageQuant and the experiment showed inhibition of 
afRio1 activity with ATP concentrations above 1.0x10-6 M (Figure 3.3A). A substrate 
inhibition plot was fit using nonlinear regression to the equation 
Vo=Vmax[S]/((Km + [S])(1+[S]/Ki)) in GraphPad Prism 5.0 (Figure 3.3B) (82, 83). 
From this fit, the parameters were determined as Vmax = 3.34 pmol/sec (± 0.07), Km = 
0.76 µM (± 0.2) and Ki = 7.15 µM (±2.28) 
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3.2 c Sedimentation equilibrium  
All protein samples were dialyzed against 50 mM Tris pH 8.0, 50 mM NaCl, 
2 mM MgCl2 and 0.2% β-mercaptoethanol. The samples were prepared in three 
different protein concentrations of 0.5 µg, 0.25 µg and 0.125 µg each in a final 
volume of 115 µl. Both phosphorylated and unphosphorylated forms of afRio1 in the 
presence of ATP/Mg2+, toyocamycin, ADP and adenosine were analyzed by this 
method. In order to ensure that there was no absorbance interference during the 
experiment from toyocamycin, ATP, ADP and adenosine, the lowest concentration 
that had no absorbance at 280 nm was 1x10-5 M for all four compounds, within 
saturation levels. The experiments were carried out at 20°C in a Beckman Coulter 
Ultracentrifuge and data was collected at 280 nm using an optical absorption 
detection and six channel Epon centerpiece with a 12 mm path length. The sample 
volume was 115 µl for the samples and 120 µl for the buffer references. Data were 
collected for all samples were three speeds; 18000, 22000 and 26,000 rpm. Raw data 
was analyzed using the software, WinNonlin (84). 
 
3.2d Site-directed Mutagenesis  
Tyr 200 was mutated to Asp using QuikChange™ Lightning kit (Agilent 
Technologies) according to the manufacturer’s instructions. Mutagenic primers used 
were 
5’GGTGCATGCGGATCTGAGCGAAGATAACATTATGTATATTGATAAA 3’ as 
the sense primer and  
5’TTTTATCAATATACATAATGTTATCTTCGCTCAGATCCGCATGCACC 3’ as 
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the antisense primer. Protein expression and purification of afRio1Y200D followed 
the same protocol as the wild-type afRio1 described in chapter 2 with only one 
modification. After lysis, the cells were heated to 68°C instead of 75°C for 15 
minutes to denature E. coli proteins.  
 
3.3 Results 
3.3a Steady state kinetics  
The Michaelis constant of afRio1 for ATP (Km,ATP) was determined to be 0.43 
µM (±0.11) and the maximum catalytic rate  (Vmax) was 2.55 pmol/sec (±0.29). The 
Km,apparent determined in the presence of a) 20 nM toyocamycin was 0.82 µM (±0.19), 
b) 40 nM toyocamycin was 0.23 µM (±0.03), and c) 60 nM toyocamycin was 0.59 
µM (±0.02) (Table 3.1). The Vmax,apparent was 1.95 pmol/sec (±0.26) in the presence of 
20 nM toyocamycin, 0.57 pmol/sec (±0.29)  in the presence of 40 nM toyocamycin 
and 0.15 pmol/sec (±0.01) in the presence of 60 nM toyocamycin (Table 3.1).  
Crystallographic data suggested that toyocamycin was a competitive inhibitor since 
toyocamycin binds in the same site as ATP. However, the inhibition studies revealed 
that in the presence of inhibitor both Vmax and Km were changing, which is 
inconsistent with strict competitive inhibition that would show a change in Km but not 
in Vmax. This suggested that in addition to competitive inhibition, an uncompetitive 
mechanism was in play and a mixed inhibition model was assumed in order to 
account for both the occupancy of toyocamycin to the ATP binding site as well as a 
change in both Km and Vmax. Mixed inhibition occurs through allosterics with either 
the inhibitor binding to a different site from the substrate’s (ATP) binding site or 
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through modulation of binding sites in oligomers. Since crystallographic data 
demonstrated that toyocamycin binds to the same site as ATP, the only other 
hypothesis was that inhibition occurred via modulation of binding sites in oligomers. 
This would imply that toyocamycin stabilizes an oligomeric form that is less 
catalytically active than the free form. However, before investigating the formation of 
oligomers, inhibition plots were fit to the mixed inhibition equation, 
Vo=(Vmax[S])/(αKm + α’[S]), where α = 1+([I]/Ki), α’=1+([I]/Ki’), and Ki and Ki’ are 
inhibition constants (Figure 3.4). The parameters α and α’ were calculated using the 
equations: Km, apparent =αKm/α’, and Vmax, apparent= Vmax/α’ respectively. The inhibition 
constants in the presence of a) 20 nM toyocamycin were 10.7 nM and 40 nM, b) in 
the presence of 40 nM toyocamycin were 26.7 nM and 11.4 nM, and c) in the 
presence of 60 nM toyocamycin were 3.8 nM and 5.5 nM (Table 3.1).  
 
3.3b Substrate inhibition by high concentrations of ATP	  
The observed inhibition of afRio1 by high concentrations of ATP can be 
explained by substrate inhibition, a phenomenon that is observed in about 20% of 
known enzymes and occurs when more than one binding site is present (82). As 
substrate concentration increases, more sites are occupied and eventually the 
enzymes’ activity is blocked (82). This is possible in oligomers that would have more 
than one binding site in a single entity. Therefore, inhibition of afRio1 by high 
concentration of ATP suggested ATP promoted oligomerization and stabilized a less 
catalytically active form of afRio1. In order to explain both mixed inhibition and 
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inhibition of afRio1 by high concentrations of ATP, sedimentation equilibrium 
experiments were carried out to determine Rio1 oligomeric states.  
 
3.3c Sedimentation equilibrium  
All data was initially fit to estimate average molecular weight using a model 
for single species: 
                                          cr= croexp[σ(r2/2-r20/2)]  
where cr is the concentration of the monomer at some radial position r, cro is the 
concentration at a reference position ro, and σ = M(1-υρ)ω2/ 2RT (M is the monomer 
molecular weight, υ is the partial specific volume of the protein, ρ is the buffer 
density, ω is the angular velocity, R is the gas constant and T is the temperature in 
Kelvin). 
In almost every case except for phosphorylated afRio1 with no ligand bound, 
a single species model resulted in a poor fit. The best fit was determined by 
minimization of the (variance) 1/2 and by examining the residuals. Data was therefore 
fit to various models; monomer, monomer-dimer, monomer-trimer, monomer-dimer-
tetramer, and monomer-tetramer equilibrium. The results of the best-fit models are 
summarized in Table 3.2. The monomeric molecular weight of afRio1 is 30.1 kDa, 
the unphosphorylated afRio1 that has residual adenosine in the active site fit to an 
average molecular weight of 60.2 kDa  (± 1.1) but the best fit was a monomer-
tetramer model, efforts to fit this data to a dimer or monomer-dimer resulted in both 
poor residuals and (variance)1/2 (Figure 3.5A). When toyocamycin is bound to 
unphosphorylated afRio1, the average molecular weight is larger than a dimer, 
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71.8 kDa (±1.2) and the best-fit model is monomer-tetramer (Figure 3.5B). In the 
presence of ATP or ADP with Mg2+, the average molecular weight was between 
monomer and dimer, 53.6 kDa (±1.1) for ATP and 50.8 kDa (± 1.1) for ADP, and the 
best-fit model for both was monomer-dimer (Figure 3.5C-D). However, when afRio1 
is phosphorylated the average molecular weight is 34.1 kDa (± 1.0) and fits to a 
monomer model, suggesting that phosphorylation prevents oligomerization (Figure 
3.5E). Interestingly when toyocamycin and ATP are added to this monomeric form of 
afRio1 (phosphorylated afRio1), oligomerization is observed with increased average 
molecular weights of 46.2 kDa (± 1.2) and 47.6 kDa (± 1.1) respectively and both 
fitting to a monomer-trimer model (Figure 3.5F-G). This data showed that in the 
presence of toyocamycin, ATP and ADP, the unphosphorylated afRio1 protein forms 
higher order oligomers and phosphorylation promotes monomerization. Addition of 
ATP and toyocamycin to the monomeric afRio1 resulted in an increased average 
molecular weight and oligomerization. Taken together the data suggested that ATP 
and toyocamycin promote oligomerization consistent with the proposed mixed 
inhibition model by toyocamycin as well as substrate inhibition of afRio1 by high 
concentrations of ATP.  
 The dissociation constants (Kd) for oligomerization were also calculated from 
the sedimentation experiments and are summarized in Table 3.2. By comparing the 
monomer-tetramer mixtures seen in solution, afRio1-toyocamycin has a lower Kd, 
1.47 x 10-6 M, compared to afRio1 with residual adenosine that has a Kd of 6.11 x 10-
6 M suggesting afRio1-toyocamycin has a tighter complex. In the presence of the two 
ligands that promote some extent of dimerization, ATP and ADP, the results showed 
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that afRio1-ATP has a tighter complex (Kd=3.12 x 10-6 M) compared to afRio1-ADP 
that has a Kd of 6.30 x 10-6 M.  
 	  
3.4 Discussion 
3.4a Understanding interacting interfaces in afRio1 oligomers. 
Sedimentation equilibrium analysis showed that afRio1 forms oligomers 
depending on the ligand bound. To better understand possible interacting interfaces 
involved in oligomerization, crystal structure lattice packing were analyzed. 
Previously solved crystal structures of unphosphorylated afRio1 with residual 
adenosine in the active site and those bound to ATP/Mn2+ and ADP/Mn2+ were 
available for analysis (24). These structures were used along with  
afRio1-toyocamycin complex structure to compare packing interfaces and identify 
structural differences that may promote formation of oligomers. It was previously 
reported that unphosphorylated afRio1 with residual adenosine differed from afRio1 
bound to ATP/Mn2+ in positioning of the flexible loop and in the conformation of  
N-lobe helices (24).  
The PDBe PISA (protein interfaces, surfaces and assemblies) server was used 
to analyze the crystal structures’ interfaces as well as calculate the buried surface area 
between the interfaces (85, 86). In the structure of afRio1-toyocamycin complex, the 
largest interface had a buried surface area of 836.5 Å2 per molecule and is observed 
between two molecules found in the asymmetric unit. The ATP/Mn2+ and ADP/Mn2+ 
bound crystal structures each have four molecules per asymmetric unit, but employ 
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the same packing interfaces observed in the afRio1-toyocamycin complex, with two 
copies of a similar dimer per asymmetric unit. The largest interface for both  
afRio1-ATP  (buried surface area 766.6 Å2) and afRio1-ADP (buried surface area 
768.4 Å2) bound structures is similar to the largest interface in the afRio1-
toyocamycin complex (Figure 3.6). This interface positions the helices of the C-lobe 
of one monomer, monomer B, in contact with both the N- and C-lobes of the second 
monomer, monomer A, almost completely occluding the active site (Figure 3.6). The 
N-lobe helix, α2, of monomer A and the C-lobe helix (αF) of monomer B interact via 
hydrogen bonds between between A:Glu 23, A:Glu 22 and B:Arg 237; A:Glu 22 and 
B:Lys 241; A:Lys 25 and B:Tyr 242; A:Glu 29 and B:Lys 168 (Figure 3.6). The C- 
lobe of monomer A interacts with the C-lobe of monomer B via hydrophobic contact 
between conserved Tyr 200 of monomer A and Leu 252, Lys 253 and Phe 248 from 
the terminal alpha helix of monomer B (Figure 3.7). In addition, there is a hydrogen 
bond between A:Glu 162 and B:Arg 233. Glu 162 also participates in a water-
mediated hydrogen bond with the 3’ OH of toyocamycin’s ribose moiety (Figure 3.7). 
This interface is not observed in the crystal structure of afRio1 with residual 
adenosine. The largest interface observed in the adenosine bound structure has a 
surface area of 1023.3 Å2 and instead positions the N-lobe of one monomer 
(monomer B) between the N- and C-lobes of a symmetry related monomer (monomer 
A (Figure 3.6). The interface is extensive and positions the first three N-terminal 
helices (α1, α2, αR) of monomer B in contact with monomer A. This interface does 
not result in occlusion of the active, and in fact, a second symmetry related molecule 
can positions its flexible loop that contains the autophosphorylation site (Ser 108), of 
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one monomer (monomer A) at the active site entrance to monomer B. Analysis of 
these interfaces reveal two different types of interaction surfaces and stabilization of 
two different types of dimers. The dimer interface observed in the crystal structure of 
afRio1-adenosine complex is different from the interface observed in the afRio1-
toyocamycin and afRio1-ATP complex. The afRio1-toyocamycin complex has the 
same packing as the afRio1-ATP/Mn2+ and afRio1- ADP/Mn2+ complexes. This 
indicates that afRio1 exists in at least two distinct dimeric or oligomeric states, and 
that the afRio1-toyocamycin complex favors the same conformation observed in the 
afRio1-ATP complex. In addition, an alignment of afRio1-adenosine, afRio1-
toyocamycin and afRio1-ATP dimers, reveals a good alignment between afRio1-
toyocamycin and afRio1-ATP whereas afRio1-adenosine does not align well with the 
other two complexes, indicative of two different types of dimers (Figure 3.8). Despite 
the fact that toyocamycin is an adenosine analog and lacks the triphosphate moiety, 
the toyocamycin bound structure favors the ATP/Mn2+ bound conformation. 
 
 3.4b Disrupting interacting interfaces and oligomerization 
Analysis of the afRio1-toyocamycin, afRio1-ATP/Mn2+ and  
afRio1-ADP/Mn2+ complexes show the involvement of one key residue, Tyr 200, in 
the interacting interfaces. This residue is either phenylalanine or tyrosine in all Rio 
kinases, and is part of the catalytic loop containing the catalytic Asp (D196 in afRio1) 
and Asn (N201 in afRio1) residues. In order to determine the importance of Tyr 200 
in dimerization of afRio1 when toyocamycin or ATP is bound, Tyr 200 was mutated 
to aspartate (Y200D) in order to disrupt aromatic hydrophobic interactions between 
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Tyr 200 and Phe 248 from the adjacent molecule, followed by oligomeric state 
analysis.  
Oligomeric state analysis of afRio1Y200D was determined using 
sedimentation equilibrium experiments in order to confirm whether this mutation was 
affecting oligomerization by disrupting interaction interfaces (Table 3.3). The 
experiments were carried out in the presence and absence of bound ligand. In the 
absence of a ligand, sedimentation equilibrium data for the Y200D mutant had an 
average molecular weight of 70.8 kDa (± 1.1) and the best fit was to monomer-
tetramer model based on evaluation of residuals as well as minimization of 
(variance)1/2 (Table 3.3, Figure 3.9A). This indicates that oligomerization is not 
significantly affected by the mutation in the unbound mutant.  However, when 
toyocamycin or ATP/Mg2+ is added, the average molecular weight drops to 48.2 kDa 
(± 1.1 kDa) and 46.8 kDa (± 1.1 kDa) respectively, with the best fit to a monomer-
trimer model in both cases (Table 3.3, Figure 3.8 B-C). The average molecular 
weights of the Y200D mutant bound to toyocamycin and ATP/Mg2+ are lower than 
that for the wild-type complexes in both cases showing more contribution from the 
monomeric species in the mutant (Table 3.3). The wild-type bound to toyocamycin 
and to ATP/Mg2+ has an average molecular weight of 71.8 kDa (±1.2) and 53.6 kDa 
(±1.1) respectively. Therefore there’s a significant change in comparison to the 
mutant average molecular weights indicating that oligomerization in the presence of 
these ligands is compromised by mutation of Tyr 200. In addition the wild-type in the 
presence of toyocamycin fits to a monomer-tetramer model yet with the mutant the 
best fit is to a monomer-trimer model. 
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3.4c Formation of different afRio1 oligomeric states 
The dimeric afRio1 structures described in this chapter (adenosine, ATP and 
toyocamycin complexes) form open oligomers that have a second interface available 
for higher order oligomerization. In addition the interacting interfaces are 
heterologous, meaning the interfaces are formed by two different surfaces from 
interacting monomers. Therefore, tetramers observed in solution and expected 
tetramers could be formed from interaction between dimers (Figure 3.10). Analysis of 
the adenosine complex revealed that interaction between dimers that utilize the 
largest interaction interface would bury an additional 1055 Å2 of surface area, and 
present the flexible loop containing the autophosphorylation site, Ser108, to the active 
site. Toyocamycin and ATP tetramers have additional buried surface areas of 881 Å2 
and 819 Å2 respectively. Therefore, it is possible that dimer formation nucleates 
higher order oligomerization, and anything that stabilizes the dimer would promote 
formation of the tetramer. In this model, trimers could be formed by addition of a 
monomer to a dimer, and would be observed when the proportion of monomer is 
increased, as seen for phosphorylated afRio1 in the presence of ATP/Mg2+ and 
toyocamycin. 
In understanding how afRio1 form higher order oligomers, it is also important 
to examine how afRio1 switches between different oligomeric forms. Toyocamycin is 
an adenosine analog and based on Thermofluor data toyocamycin binds with a higher 
affinity and stabilizes afRio1 more than ATP/Mg2+. Despite these results afRio1-
toyocamycin complex adopts the same conformation as the afRio1-ATP complex.  
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This is contradicts predictions that due to their very similar structures, toyocamycin 
and adenosine would adopt the same conformation and stabilize the same type of 
oligomers. Therefore, the hypothesis was that there must be a structural 
conformational change or switch that influences the choice of interacting interface 
conserved between the ATP and toyocamycin bound structures but is different in the 
adenosine bound structure. Upon closer inspection of the active sites of the afRio1 
structures with adenosine, toyocamycin and ATP bound, a difference in positioning 
of the metal binding loop containing the metal binding residue, Asp 212 was observed 
(Figure 3.11). Specifically, in the adenosine bound structure, the backbone carbonyl 
oxygen bond of Ile 211 points into the binding pocket towards the nucleoside, while 
in the ATP and toyocamycin bound structures, there is a peptide flip that positions the 
same carbonyl oxygen in the opposite direction. This results in a 3.8 Å shift in the 
carbonyl oxygen position producing a shift in the metal binding loop containing 
residues Ile 211 to Gln 215. Subsequently the Cα of Gln 215, a residue that is 
conserved in all RIO kinases, is shifted by 2.1 Å and the side chain is within 
hydrogen bonding distance to Asp 212 carboxylate oxygen. The flexible loop of 
afRio1 bound to toyocamycin and ATP is shifted away away from the active site and 
a shift in the catalytic loop is also observed (Figure 3.11).  
 
3.5 Summary 
    Despite crystallographic studies that show binding of toyocamycin to the 
ATP binding site that suggests strict competitive, steady state kinetics revealed mixed 
inhibition as the mode of inhibition. In addition to inhibition by toyocamycin, 
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substrate inhibition of afRio1 by high concentrations of ATP is observed. Both mixed 
inhibition and substrate inhibition are supported by formation of oligomers in the 
presence of toyocamycin and ATP.  These oligomers are less catalytically active than 
the afRio1 free form. Analysis of interacting interfaces and formation of oligomers 
reveals the stabilization of two different types of dimers as a result of conformational 
switches. AfRio1-ATP and afRio1-toyocamycin complexes form the same type of 
dimer whereas the afRio1-adenosine forms a different type of dimer based on 
alignment and interface analysis. These dimers are open, heterologous and are 
therefore capable of forming higher order oligomers.  This validates the monomer-
trimer and monomer-tetramer models that are observed in solution. The question 
remained whether afRio1 studies are applicable to eukaryotic Rio1. The answer to 































Figure 3.1: Plots of moles of γ-32phosphate incorporated as a function of time. 
The plots represent the average moles of γ-32phosphate since reactions were done in 
triplicates. Initial velocity (Vo) was determined as the linear slope. A. Plot of afRio1 
with no toyocamycin added to the reaction mixtures. B. Plot of afRio1 with 60 nM 
toyocamycin added to reaction mixtures. C. Plot of afRio1 with 40 nM toyocamycin 
















Figure 3.2: Inhibition of afRio1 phosphorylation activity by toyocamycin. Plot of 
initial velocity (Vo) as a function of ATP concentration. This plot was generating by 
fitting the plot of moles γ-32phosphate incorporated as a function of time to the 
Michealis-Menten equation, Vo = (Vmax [S])/(Km + [S]). From the plots, the Vmax, Km, 


















































Figure 3.3: Substrate inhibition. A. Gel showing inhibition of afRio1  
phosphorylation activity by high concentrations of ATP above 1 µM. B. Graph fit to 



























Figure 3.4: Schematic of mixed inhibition.  
 
 
















Km (µM) 0.43 (±0.11) 0.82 (±0.19) 0.23 (±0.03) 0.59 (±0.02) 
Vmax  
(pmol/sec) 
2.55 (±0.29) 1.95 (±0.26) 0.57 (±0.29) 0.15 (±0.39) 
Ki (nM)  10.7 26.7 4.6 
Ki’ (nM)  40.0 11.4 8.5 
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Table 3.2: Sedimentation equilibrium data for afRio1 bound to various ligands. 









































8.0 x 10-3 
 




71.8 ± 1.2 Monomer-
tetramer 
1.8 x 10-2 1.47 x 10-6 
 




2.8x 10-2 3.12 x 10-6 
 
afRio1+ADP 50.8 ± 1.1 Monomer-
dimer 




34.1 ± 1.0  Monomer 3.1 x 10-2 N/A 
Phosphorylated 
afRio1+ATP  
47.6 ± 1.1  Monomer-
trimer 








1.3 x 10-2 6.38 x 10-6 




Figure 3.5: Sedimentation equilibrium data collected at three speeds 18,000 rpm 
(blue), 22,000 rpm (green) and 26,000rpm (red). The fitted data was analyzed at 
three speeds and at the same concentration (0.25 µg/µl). A. AfRio1 with residual 
adenosine. B. AfRio1 with toyocamycin bound. C. AfRio1 with ADP bound. D. 
AfRio1 with ATP bound. 
A.	   B.	  
C.	   D.	  




















Figure 3.5: Sedimentation equilibrium data collected at three speeds 18,000 rpm 
(blue), 22,000 rpm (green) and 26,000rpm (red). The fitted data was analyzed at 
three speeds and at the same concentration (0.25 µg/µl). Each plot is accompanied 
with the respective residuals. E. Phosphorylated afRio1. F. Phosphorylated afRio1 
with ATP bound. G. Phosphorylated afRio1 with toyocamycin bound. 
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Figure 3.6: Dimer interfaces. The N-lobe of monomer A is in magenta and the C-
lobe is in cyan whereas monomer B is in green. A. AfRio1-toyocamycin dimer with 
the C-lobe of monomer B interacting with N and C-lobes of monomer B.  
B. AfRio1-ATP dimer with the C-lobe of monomer B interacting with N and C-lobes 
of monomer B. C. AfRio1-adenosine with the N-lobe of monomer B interacting 
between the N and C-lobes of monomer A.  
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Figure 3.7: AfRio1-toyocamycin dimer interface. AfRio1-toyocamycin dimer 
interface showing hydrogen bonds ( dashed black lines) between the C-lobe of 
monomer B and the N- and the C-lobes of monomer A. The dimer interface also 
indicates the occlusion of the active site and hydrophobic contact between conserved 
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Figure 3.8: Alignment of afRio1 dimers. AfRio1-ATP is in red, afRio1-
toyocamycin is in cyan and afRio1-adenosine is in yellow. AfRio1 bound to ATP and 
toyocamycin align well whereas afRio1 with adenosine does not align well with the 
other two dimers. This is evident of two different types of dimers, the ATP and 
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Figure 3.9: Sedimentation Equilibrium data for afRio1 Y200D mutant. A. 
Y200D mutant with no ligand bound. B. Y200D with ATP bound. C. Y200D with 




















afRio1 Y200D 70.6 ± 1.1  Monomer-
tetramer 




48.2 ± 1.1  Monomer-
trimer 
9.3 x 10-3 1.20 x 10-5 
afRio1Y200D 
+ATP 
46.8 ± 1.1  Monomer-
trimer 
9.4 x 10-3 7.32 x 10-6 
A.	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C.	  

























Figure 3.10: AfRio1 tetramers. ATP and toyocamycin stabilize the same type of 
tetramer, different from the afRio1-adenosine tetramer. A. AfRio1-ATP tetramer, 
each monomer has ATP bound. B. AfRio1-toyocamycin tetramer, each monomer as 























Figure 3.11: Alignment of afRio1 active site. Structural conformation switch 
observed in afRio1 bound to ATP (magenta), toyocamycin (cyan) and adenosine 
(yellow). The peptidyl carbonyl group of Ile 211 points towards the binding site in the 
adenosine complex whereas in toyocamycin and ATP this group points away from the 
binding site. This positions Asp 212 within hydrogen bonding distance to Gln 215 in 
the toyocamycin and ATP bound complexes. A shift is observed in the metal binding 
loop, the catalytic loop and the flexible loop. This conformation changes led to two 
different oligomers, toyocamycin and ATP stabilize the same type of oligomer 
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Chapter 4: Structural Determination and Biochemical Studies of Human Rio1 
Kinase (RioK1). 
 
 4.1 Introduction 
          Studies show that human Rio1 Kinase (RioK1) is over-expressed in colon 
cancer cells and recent reports link RioK1 to rRNA processing via recruitment of 
nucleolin to the human protein arginine methyltransferase complex (PRMT5) (47, 
53). Nucleolin is a eukaryotic protein involved in ribosome biogenesis that is 
methylated by PRMT5 complex, thereby modulating nucleolin’s interaction with 
rRNA (47). Immunoprecipitation and pull-down assays to identify potential 
interacting protein partners for RioK1 identified nucleolin and PRMT5. RioK1 
interaction with PRMT5 is well documented as being stoichiometric and the 
interaction occurs via the N-terminal of PRMT5 and residues 1-242 of RioK1. (47) 
(87). Despite these discoveries, RioK1 substrates have not yet been identified, its 
biological function and mechanistic details are not fully understood and there are no 
reports of a eukaryotic Rio1 crystal structure. The availability of a RioK1 crystal 
structure would not only provide the first eukaryotic Rio1 structure but would also aid 
in addressing some of the unknowns.  
RioK1 crystallographic studies were initially carried out with a RioK1 
construct comprised of residues 106-494 that had been cloned by my advisor Dr. 
LeBlanc. Results from this construct initiated optimization studies that included 
limited proteolysis in order to determine a stable RioK1 construct and surface entropy 
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mutagenesis (SER) in order to obtain well-ordered, better diffracting crystals of 
RioK1 (106-494). SER targets surface residues found in clusters that have large 
hydrophilic side chains and replaces them with small amino acids such as alanines. 
Mutation of surface residues has the promise of generating x-ray quality crystals with 
some reports indicating an increase of resolution by more than 1 Å (88, 89). The 
rationale is that these surface modifications lead to reduction of conformational 
entropy and generate homogenous surface patches (88).  
The free energy (∆G) that drives crystallization is a sum of enthalpy of 
intermolecular interactions in the crystal (∆H), protein entropic changes (∆Sprotein) and 
solvent entropic changes (∆Ssolvent) as shown in the equation below:  
                                    
                     ∆G= ∆H –T (∆Sprotein+ ∆Ssolvent) 
Equation 4.1: Free energy that drives crystallization 
 
Crystallization is more sensitive to both protein and solvent entropic changes and less 
so to enthalpic effects (88). Proteins with surfaces populated with large hydrophilic 
residues have side chains with high conformational entropy due to flexibility of the 
side chains. This inhibits crystallization by increasing the entropic barrier that must 
be overcome to order and bury these residues at points of crystal contacts (90) . In 
addition, these large hydrophilic residues have a large surface exposed to solvent 
preventing intermolecular contacts necessary for crystallization. Therefore replacing 
the large residues with smaller residues that have low conformational entropy favors 
the formation of crystal contacts and more ordered crystals (90).  Mutational studies 
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have shown that lysine and glutamate are the best large hydrophilic targets whereas 
alanine is the most suitable small residue to replace Lys or Glu (91). The 
experimental and results of SER mutants for RioK1 will be described in more detail. 
This chapter presents the first eukaryotic Rio1 crystal structure and compares 
the structure to the archaeal Rio1’s crystal structure to determine whether evolution 
led to distinct structural features. In addition, biochemical studies including 
identification of autophosphorylation sites, substrate inhibition, affinity for potential 
Rio1 inhibitors and formation of oligomeric states are presented. Archaeal Rio1 
(afRio1) studies revealed a high affinity for toyocamycin, substrate inhibition by high 
concentrations of ATP and formation of oligomeric states in the presence of different 
ligands. Similar biochemical studies were carried out using RioK1 to determine if any 
of these trends are in eukaryotic Rio1. 
  
4.2 Experimental Procedures:  
4.2a Expression and purification of RioK1 (106-494). 
  Initial attempts to express full-length RioK1 were not fruitful despite efforts to 
optimize the expression protocol by varying the concentration of Isopropyl β-D-1-
thiogalactopyranoside (IPTG), trying expression at different temperatures and using 
different E.coli strains. A new construct of RioK1 residues 106-494 was cloned based 
on secondary structure prediction and incorporation of the RIO domain, residues 180 
to 479. RioK1 (106-494) expression vector with a T7-promoter, an N-terminal 
histidine tag, a Tobacco Etch Virus (TEV) site and gene sequence was transformed to 
Rosetta(DE3) pLysS E.coli cells (Novagen). The cells were plated on Lysogeny 
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Broth (LB) Agar plates containing 100 µg/mL ampicillin and 34 µg/mL 
chloramphenicol and incubated at 37°C for 16 hours. Colonies were inoculated into 
40 mL of LB media with 100 µg/mL of carbenicilin and 34 µg/mL of 
chloramphenicol and grown overnight at 37°C while shaking at 250 rpm. The 
overnight culture was added to 4L of LB media with 100 µg/mL ampicillin and 34 
µg/mL chloramphenicol and grown at 37°C while shaking at 250 rpm until the OD600 
was between 0.6 and 0.8, the mid-log phase. These cells were induced with 1 mM 
IPTG at 20°C for 18 hours and then centrifuged at 6,000 rpm and 4°C for 30 minutes. 
The bacterial pellet was stored at -80°C and later resuspended in lysis buffer 
containing 50 mM Tris pH 8.0, 200 mM NaCl, 2 mM MgCl2, 1 mM ATP, 0.2 % β-
mercaptoethanol, 0.1 mg/mL DNAse and 0.3X Bugbuster . The resuspended cell 
pellet was gently stirred on ice for 45 minutes, transferred to pre-cooled centrifuge 
tubes and immediately centrifuged at 18,000 rpm and 4°C for 30 minutes. The 
supernatant was filtered and loaded onto a pre-equilibrated 5 mL HisTrap column 
(GE healthcare) attached to a Fast Protein Liquid Chromatography (FPLC) system at 
a flow-rate of 2.5 mL/min. The HisTrap column was washed with 10 column volumes 
of lysis buffer to remove any unbound protein. Bound RioK1 (106-494) protein was 
subjected to an imidazole gradient of 100 mM to 1 M and the protein eluted between 
150 mM and 300 mM. Partially purified fractions were pooled together and 
transferred to a dialysis membrane to which 1 mg/mL Tobacco etch virus (TEV) 
protease, needed to cleave the histidine tag, was added. The protein was dialyzed 
overnight at 4°C into 50 mM Tris pH 8.0, 200 mM NaCl, 50 mM Tris pH 8.0, 1 mM 
ATP, 2 mM MgCl2 and 0.2 % β-mercaptoethanol  and then loaded onto a 5 mL 
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HisTrap column pre-equilibrated with lysis buffer. The HisTrap column was washed 
with lysis buffer to elute cleaved RioK1 (106-494) that was further purified by size 
exclusion chromatography using Superdex 200 (GE healthcare) pre-equilibrated in 50 
mM Tris pH 8.0, 200 mM NaCl, 1 mM ATP, 2 mM MgCl2, 10 % glycerol and 0.2 % 
β-mercaptoethanol. All purification steps were monitored by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS PAGE) for purity (Figure 4.1). 
 
4.2b Crystallization, data collection, processing and refinement of  
RioK1 (106-494)  
           Purified RioK1 (106-494) was concentrated to 25 mg/mL and subjected to 
robotic sparse matrix screening using Phoenix Liquid Handing System (Art Robbins). 
Commercially available matrix screens, Index (Hampton), Cyros (Qiagen), PEGs 
suite (Qiagen), Wizard I, II, III (Emerald Biosystems) were used for initial crystal 
screening in 96-well plates by the sitting drop method in three different protein to 
well solution ratios (1:2, 1:1, 2:1). Needle-shaped crystals were observed in PEGs 
Suite in a 2:1 protein to well solution ratio (Figure 4.2 A-B). These crystals grew in 
0.2M Ca(OAc)2, 20% PEG 400, pH 8.0 and optimized by varying both the 
concentration of precipitant, PEG 400, and pH to generate diffraction quality crystals. 
Optimized crystals were flash frozen in their well conditions with 20% (v/v) glycerol 
as a cryoprotectant. Data collection was done at 100K at the NE-CAT beamline at 
Argonne, IL.  The best diffraction was to 3.50 Å and this data was indexed, integrated 
and scaled using HKL2000 (71). The crystals belonged to P3221 space group and the 
unit cell dimensions were a=78.99, b=78.99, c=110.45 and α=90°, β=90° γ=120°. An 
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output file that is necessary to determine the quality of data collected based on 
redundancy, data completeness and Rsymm values is shown in Table 4.1. Attempts to 
solve the structure by molecular replacement using afRio1 (PDB ID: 1ZP9) as a 
search model were not successful. This is in part due to the low sequence identity, 
21%, shared between RioK1 and afRio1 as well as the low-resolution data. The 
alternative was to generate selenium–derivatized crystals (Se-Met) and solve the 
structure by single wavelength anomalous dispersion (SAD).  
 
4.2c Expression, purification and data collection of Se-Met RioK1 (106-494) 
A glycerol stock of RioK1 (106-494) was inoculated in 40 mL of LB media 
with 100 µg/mL of carbenicilin and 34 µg/mL of chloramphenicol and grown 
overnight at 37°C while shaking at 250 rpm. The overnight culture was centrifuged at 
5,000 rpm for 20 minutes at 4°C. The bacterial pellet was resuspended with M9 
selenomethionine growth media (Medicilon) that was prepared according to the 
manufacturer’s protocol and then added to 4L of M9 SeMet media with 100 µg/mL 
ampicillin and 34 µg/mL chloramphenicol. The cells were grown at 37°C while 
shaking at 250 rpm until the OD600 was close to 1.2. Inhibitory amino acids and 
selenomethionine were added to the cells according to the manufacturer’s protocol 
and the cells were transferred to 20°C for 15 minutes. Cells were then induced with  
1 mM IPTG at 20°C and grown for 18 hours. The following day the cells were 
centrifuged at 6,000 rpm and 4°C for 30 minutes. Purification of Se-Met RioK1 (106-
494), crystal screening and optimization followed the same protocol as the native 
protein. Se-Met RioK1 (106-494) crystals were observed in the same conditions as 
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the native crystals.  
Se-Met RioK1 (106-494) crystals had the same crystal form and space group 
as native crystals. The crystals diffracted to 3.50 Å and data was collected at one 
wavelength, 0.97915 Å (Figure 4.2 C). The cell dimensions were a=79.52, b=79.52, 
c=110.86 and α=90°, β=90° γ=120° with an overall redundancy of 2.0, an Rsymm of 
28% and 98% data completion (Table 4.2).  
 
4.2d Surface Entropy Mutagenesis (SER) 
 The surface entropy mutagenesis prediction (SERp) server from UCLA was 
used to identify Lys 269 and Glu 270 as good targets for mutation in RioK1 (106-
494) (92) . Primers for the double mutant RioK1 K269AE270A were designed and 
site-directed mutagenesis carried out using QuikChange lightning kit (Agilent) 
according to the manufacturer’s instructions.  Expression, purification and initial 
crystal screening of RioK1 K269AE270A followed the same protocol as that of 
RioK1 (106-494). Tiny needle-shaped crystals were observed in Wizard III screen 
and grew in 24% PEG 3350, 0.1 M HEPES pH 5.3 and 0.2 M CaCl2 (Figure 4.3).  
These crystals were not reproducible and therefore could not be optimized. Crystals 
obtained from the initial screen did not diffract.  
 
4.2e   Limited Proteolysis  
  In order to determine a stable fragment of RioK1, the protein was subjected to 
proteolysis in of three different proteases; trypsin, thermolysin and elastase. For the 
trypsin and thermolysin reactions, 5 mg/mL of RioK1(106-494) in 100 mM Tris pH 
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8.0, 100 mM NaCl and 5 mM CaCl2 was treated with 1 mg/mL of the protease at 
37°C. For the elastase reaction 5 mg/mL of RioK1 in 200 mM Tris pH 8.0 was 
treated with 1 mg/mL of elastase at 37°C. All reactions were subjected to a time-
based assay and stopped at 0, 10, 30, 60 minutes and 24 hours by denaturing the 
protease. In order to visualize the most stable fragment, all reactions were run on a 
preparative SDS-PAGE gel and the most stable fragment (25kDa) appeared after 10 
minutes and was present after 24 hours (Figure 4.4). The band representing this 
fragment was cut from the gel and analyzed by in-gel trypsin digest followed by 
peptide identification using tandem mass spectrometry (tandem-MS/MS). Mass 
spectrometry analysis was done at the University of Maryland proteomics center by 
Dr. Yan Wang. The fragment was identified as residues 252-468, which does not 
incorporate the full RIO domain, residues 180-479 (Figure 4.5). From RioK1 (106-
494) preparative gels, it was evident that this construct was subject to degradation; a 
band just below RioK1 (106-494) was consistently present in all purification steps 
(Figure 4.1). The next approach was to identify this fragment and clone the construct.  
 
4.2f RioK1 (143-494): Cloning, expression, purification and crystallization. 
  The band representing RioK1 (106-494) degradation was cut from the gel and 
sent to Proteomics center for in-gel trypsin digest and analysis by tandem-MS/MS.  
Peptide identification data revealed that degradation was from the N-terminus of 
RioK1 (106-494) and the fragment comprised of residues 143 to 494 (Figure 4.6). 
RioK1 (143-494) was cloned using Gateway technologies (Invitrogen). Two gene-
specific primers were designed for cloning; the sense primer 5’GAG AAC CTG TAC 
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TTC CAG GGC GAA GCG GAT ATG TAT CGC ATT AAA GCG -3’ that contains 
a sequence for Tobacco Etch Virus (TEV) cleavage site in red, and the antisense 
primer 5’ GGGG ACC ACT TTG TAC AAG AAA GCT GGG TTA TCA GGT 
GCG TTC TTC CAC CTG GTT TTC 3’ that contains a recombinant site, attb2, 
shown in bold. These primers along with the full-length RioK1 DNA were subjected 
to a polymerase chain reaction (PCR) after which the PCR product was subjected to a 
second reaction using a “piggyback primer” (Invitrogen) 5’-GGGG ACA AGT TTG 
TAC AAA AAA GCA GGC TCG GAG AAC CTG TAC TTC CAG that contains 
the second recombinant site, attb1, in bold as well as a TEV site in red. The final PCR 
product was introduced into an entry vector, pDONR 201 (Invitrogen), and finally 
into a destination vector, Pdest 527 (Invitrogen) that contains a T7 promoter and an 
N-terminal 6X histidine tag sequence. RioK1 (143-494) expression vector was 
transformed to Rosetta (DE3) pLysS E.Coli cells (Novagen) and expression carried 
out in SelenoMethionine expression media (Shanghai Medicilon Inc) according to the 
manufacturer’s instructions. Purification of Se-Met RioK1 (143-494) followed the 
same protocol as RioK1 (106-494). Purified Se-Met RioK1 (143-494) with 
ATP/Mg2+ bound was concentrated to 20 mg/mL and subjected to robotic sparse 
matrix screening using Phoenix Liquid Handling system (Art Robbins) (Figure 4.7). 
Rod-shaped crystals were observed in Wizard III screen in both the 1:1 and 2:1 
protein to well solution ratios. These crystals grew in 28% PEG 400, 0.1M HEPES 
pH 7.5, 0.2M CaCl2 and were optimized by varying the concentration of precipitant, 
PEG 400, and the pH (Figure 4.8). Optimized crystals were flash frozen in their well 
solution with 20% (v/v) ethylene glycol as a cryoprotectant and shipped to Argonne 
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National Labs for data collection and processing.  
 
4.2g Data collection, processing and refinement of RioK1 143-494 
 Data was collected at one wavelength (0.97915 Å), indexed, integrated and 
scaled using the HKL2000 package program as with previous crystals (71). The best 
diffraction was to 2.63 Å and the space group was P32.	  The unit cell dimensions were 
a=78.81Å, b=78.81Å, c= 110.57Å, α=90.000, β=90.000, γ=120.000 an overall 
redundancy of 4.5, 95.9% data completion and an overall Rsymm of 10.6% (Table 4.5). 
The structure was solved using an automated experimental phasing program, 
AutoSol, that’s part of PHENIX (93). AutoSol finds heavy atom sites using hybrid 
substructure search (HYSS) then calculates experimental phases using Phaser and 
improves the phases by density modification using RESOLVE (94-96). After 
obtaining density-modified phases the program carries out a round of model building 
and refinement. The initial RioK1 (143-494) model was subjected to two rounds of 
model building using AUTOBUILD that’s part of PHENIX (97-100). Subsequent 
rounds of model building were carried out in COOT accompanied by rounds of 
refinement using PHENIX and REFMAC5 that’s part of CCP4i (74-76). Waters were 
added to the structure using COOT and the final model had a Rwork/Rfree of 22.8/26.6 
(Table 4.5). The refined crystal structure had two molecules per asymmetric unit 
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4.2h RioK1 autophosphorylation sites 
A sample of purified RioK1 (106-494) was first analyzed for mass 
determination by electrospray ionization (ESI) and the results revealed three peaks on 
the deconvoluted spectrum (Figure 4.14). The first peak corresponded to the expected 
molecular weight of 45126.18 Daltons, the second and third peaks corresponded to 
singly (45203.69 Daltons) and doubly (45279.67 Daltons) phosphorylated RioK1 
(106-494) respectively (Figure 4.14). In order to identify the autophosphorylation 
sites, the RioK1 sample was subjected to trypsin digest followed by tandem-MS/MS 
for peptide identification. This work was done in collaboration with Dr. Yan Wang at 
the University of Maryland Proteomics center. For analysis the expected molecular 
weight (MW) of various peptide fragments was compared to the observed MW in 
order to determine fragments that contained phosphorylation sites. One site, serine 
130 was identified with certainty but it was ambiguous whether the second site was 
serine 415 or serine 416 since both were on the same peptide fragment. To address 
this ambiguity, Ser 415 and Ser 416 were mutated to alanines followed by 
autophosphorylation assays to determine the second site.  
 
4.2i Autophosphorylation sites: Mutagenesis and Assay 
Primers for mutants RioK1 (106-494) S130A, S415A and S416A were 
designed and site-directed mutagenesis was carried out using QuikChangeTM 
Lightning kit (Agilent) according to manufacturer’s instructions (Table 4.6). Three 
single mutants S130A, S415A and S416A and two double mutants S130AS415A and 
S130AS416A were expressed and purified following the protocol for wild-type 
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RioK1 (106-494) with one exception, 1 mM ATP was substituted for 500 µM 
adenosine in all the buffers. Adenosine was used in these purifications to prevent any 
autophosphorylation activity before the actual assays. Autophosphorylation assays 
were carried out by adding 10 µg of wild-type RioK1 (106-494) and mutants to a 30 
µl reaction volume in a buffer containing 50 mM Tris pH 8.0, 200 mM NaCl, 500 µM 
adenosine, 2 mM MgCl2 and 0.2 % β-mercaptoethanol. 1 µM of γ-32P labeled ATP 
was added to all reactions and incubated at 25°C for 1 hour. The reactions were done 
in triplicates and stopped by adding 8 µL of SDS loading buffer and heating at 95°C 
for 5 minutes to denature the protein. All reactions were run on a NuPAGE™ 4-12% 
Bis-Tris denaturing gel (Invitrogen) to separate the protein from γ-32P labeled ATP. 
The gel was dried, exposed onto a phosphorimager screen for 15 hours and quantified 
using ImageQuant to determine autophosphorylation activity based on amount of γ-
32phosphate incorporated into the protein (Figure 4.15 A). 
 
4.2j RioK1 Thermofluor Assay 
A Thermofluor assay was used to test the affinity of RioK1 for toyocamycin, 
sangivamycin, 7-methylinosine and ATP/Mg2+. 1.0 mg/mL of purified RioK1 was 
incubated at 4°C for 1 hour with 2 mM of toyocamycin, sangivamycin, 7-
methylinosine and ATP/Mg2+ in a buffer containing 50 mM Tris pH 8.0, 200 mM 
NaCl, 2 mM MgCl2, 0.2 % β-mercaptoethanol and 1 mM ATP. The control reaction 
was RioK1 with no ligand added. After incubation, Sypro-OrangeTM fluorescent dye 
(Sigma-Aldrich) was added to the reactions and heated from 4°C to 98°C at a rate of 
0.2°C per second using Bio-Rad Mini-Opticon thermal cycler. Measurements were 
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done in triplicates and the Tm was determined as the inflection point of the melting 
curve. The change in Tm was calculated as the difference between the Tm of bound 
RioK1 and Tm of unbound RioK1. 
 
4.2 k Substrate inhibition at high concentrations of ATP 
An autophosphorylation assay was carried out to test whether RioK1 activity 
is inhibited by high concentrations of ATP. In this assay, 5 µg of RioK1 was added to 
a buffer containing 20 mM Tris pH 8.0, 100 mM NaCl, and 2 mM MgCl2. The 
concentration of γ-32P labeled ATP was varied from 1800 µM to 0.9 µM. All RioK1 
reactions were incubated at 25°C for 1 hour and components separated by running a 
denaturing gel. Autophosphorylation activity was determined by quantifying the gels 
using ImageQuant. 
 
4.2l Size Exclusion chromatography  
Size exclusion chromatography (SEC) was used to determine oligomeric 
states in the presence of 2 mM adenosine and ATP/Mg2+ as well as phosphorylated 
RioK1. All samples had a final protein concentration of 3 µg/µl and were analyzed 
using an analytical Superdex 200 column (GE Healthcare) that was pre-equilibrated 
with a buffer containing 50 mM Tris pH 8.0, 200 mM NaCl, 2 mM MgCl2 and 0.2 % 
β-mercaptoethanol. In order to calculate the estimated molecular weight of RioK1 
samples, calibration proteins (GE healthcare); ribonuclease (13kDa), ovalbumin 
(43kDa), conalbumin (75kDa) and aldolase (158kDa) were also analyzed by SEC. 
Calibration proteins were diluted with 50 mM Tris pH 8.0 and 200 mM NaCl for a 
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final concentration of 3 µg/µl, mixed together, centrifuged to remove any precipitants 
and loaded onto the analytical Superdex200 column.  
 
4.3 Results  
4.3a Se-Met RioK1 (106-494) 
Attempts to solve RioK1 (106-494) by SAD phasing were not successful due 
to a low anomalous signal as a result of radiation damage during data collection and 
possible oxidation of selenium atoms. In addition the data set should have been cut 
back to about 3.9 Å during scaling since beyond this resolution, the Rsymm is above 
0.5, which is generally the cut-off fraction and inclusion of this data resulted in the 
high overall Rsymm value of 28%. The redundancy was also below the acceptable 
value of 3.0 and above. This is usually resolved by collecting more data as long as the 
crystal does not succumb to radiation damage. The resulting electron density map 
lacked enough detail to properly model in the protein. After several attempts at model 
building and refinement in PHENIX and COOT, the Rwork/Rfree did not dropped below 
41.1/45.5% indicative of poor agreement between the model and the original x-ray 
data (75, 76). Se-Met RioK1 (143-494) with ATP/Mg2+ resulted in better diffracting 
crystals that were used to solve the first crystal structure of a eukaryotic Rio1 kinase. 
 
4.3 b Overall Structure of RioK1 (143-494) with ATP/Mg2+ bound. 
The overall RioK1 (143-494)-ATP /Mg2+ structure consists of an N-lobe that 
has the helix αR, and a twisted β sheet that contains the nucleotide binding loop (p-
loop) whereas the C-lobe is helical and houses the catalytic and metal binding loops 
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(Figure 4.9). Both N- and C-lobes are connected by a hinge region that buries the 
adenine ring of ATP. The RioK1 (143-494)-ATP /Mg2+ overall structure is consistent 
with the general features of kinases that contain an N-lobe comprised of a twisted β-
sheet and a helical C-lobe (10, 29).  
Electron density is not observed for residues 143-163 that corresponds to the 
subfamily-specific N-terminal helices (α1 and α2) and on the C-lobe there is no 
density for residues 431-494 on chain A and residues 429-494 on chain B. Lack of 
electron density on the N- and C- terminus is due to disorder and flexibility of these 
regions. The structure also lacks electron density for residues 212-243 that consists of 
the flexible loop.  This is similar to the structure of afRio1-ATP/Mg2+ complex for 
which no electron density is observed for residues 85-91 that’s part of the flexible 
loop (24). An alignment of the two molecules of RioK1 (143-494)-ATP /Mg2 in the 
asymmetric unit revealed an RMSD of 0.237 Å over 192 residues (Figure 4.10).  
An alignment of afRio1-ATP/Mn2+ and RioK1 (143-494)-ATP/Mg2+ dimer 
structures had an RMSD of 0.894 Å over 158 residues and shifts on the N-lobe and 
the metal binding loop on the C-lobe were observed (Figure 4.11A). The N-lobe 
helix, αR, on RioK1 (143-494) is shifted 3.0Å away from afRio1’s αR resulting in a 
shift on the N-lobe twisted β sheet and the nucleotide-binding loop (p-loop) (Figure 
4.11). Subsequently shifts are observed on the hinge region and the metal binding 
loops (Figure 4.11). RioK1 (143-494) metal binding loop is shifted 1.1 Å away from 
afRio1’s metal binding loop. In addition, the RioK1 (143-494)-ATP complex shows 
the γ-phosphate of ATP positioned and orientated differently compared to what’s 
observed in the afRio1-ATP complex.  
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4.3 c RioK1 (143-494) interactions with ATP  
The RioK1 (143-494)-ATP /Mg2+ structure shows ATP buried in a pocket that 
features hydrophobic contact with Ile 186, Val 194, and Ala 206 from the N-lobe; 
Met 277, Phe 279, Ile 280 and Pro 286 from the hinge region; Leu 331 and Ile 340 on 
the metal-binding loop, from the C-lobe (Figure 4.12A). These hydrophobic 
interactions are very similar to the ones observed in the afRio1-ATP/Mn2+ complex 
(24). In addition to hydrophobic contacts, ATP participates in several hydrogen bond 
interactions that are either direct or water-mediated. There is a direct hydrogen bond 
from the peptidyl carbonyl oxygen of Ser 278 on the hinge region to the amine group 
at N6 position on the adenine ring (Figure 4.12B). In the afRio1-ATP/Mn2+ structure 
this interaction is between the amine group at N6 and the peptidyl carbonyl oxygen of 
Glu 148 (24). Two hydrogen bonds are observed; one from the indole nitrogen (N1) 
to the peptidyl amine group of Ile 280 on the hinge (Figure 4.12B) and another bond 
between Lys 208 and an α-phosphate oxygen. Similar interactions are observed in the 
afRio1-ATP complex (24).There is a metal-mediated interaction between the catalytic 
residue, Asn 329, to the α, β and γ-phosphate oxygens of ATP (Figure 4.12B). There 
is an additional metal-mediated interaction between Mg2+ to the metal binding 
residue, Asp 341, to the α, β and γ-phosphate oxygens of ATP (Figure 4.12B).  Both 
metal-mediated interactions are similar to the ones observed in the afRio1-ATP/Mn2+ 
complex with the metal binding residue Asp 212 and the catalytic residue Asn 201 
(24). Water-mediated hydrogen bonds are observed between Ser 187 of the p-loop 
and a β-phosphate oxygen of ATP and between Glu 191 of the p-loop and the β- and 
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γ-phosphate oxygens of ATP (Figure 4.12B). A key difference between RioK1 (143-
494)-ATP/Mg2+ and afRio1-ATP/Mn2+ complexes is the distance between the 
catalytic aspartate and the γ-phosphate oxygen of ATP.  In the RioK1 (143-494)-ATP 
/Mg2+ this distance is 3.3 Å whereas in afRio1-ATP/Mn2+ this distance is 5.1 Å. The 
difference in this distance can be attributed to the shift in the metal binding loop as 
well as the orientation and positioning of the γ-phosphate. This is suggestive of a 
difference in the catalytic rate activity between eukaryotic Rio1 and afRio1.  
Therefore despite evolution, both eukaryotic RioK1 and archaeal Rio1 share almost 
identical interactions with ATP.  
  
4.3d Potential candidates for dimer interfaces 
The computational database, PDBe PISA (protein interfaces, surfaces and 
assemblies) server, was used to analyze RioK1 (143-494)-ATP/Mg2+ potential 
interacting interfaces and calculate the buried surface area. The largest interface had a 
buried surface area of 564.3 Å2 per molecule and is observed between the two 
molecules in the asymmetric unit. This interface is characterized by interactions 
between the hinge region of monomer A and the C-lobe residues of monomer B 
(Figure 4.13A). This interface is characterized by poor packing and only two 
hydrogen bonds are observed, one between Lys 401 of monomer A and Asp 284 of 
monomer B and another between Asp 387 of monomer A and Lys 282 of monomer B 
(Figure 4.13A). The second potential interface is between symmetry related 
molecules and has a calculated surface area of 429.1 Å2 per molecule. The interface is 
observed between αC on the N-lobe of molecule A and C-lobe residues of molecule 
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B (Figure 4.13B). This interface is characterized by hydrophobicity, a characteristic 
of biological interface, and better packing than the first interface between two 
molecules per asymmetric unit. This second interface has hydrogen interactions 
between: Glu 413 of A and Arg 319 of B; His 419 of A and Thr 259 of B; Gln 417 of 
A and Arg 252 of B; and Arg 427 of A and peptidyl carbonyl oxygens of Arg 271 of 
molecule B (Figure 4.13 B). Hydrophobic contacts are observed between Val 421 of 
A and Ile 255 of B; Val 424 of A and Met 251 of B; and Ala 428 of A and Leu 270 of 
B.  Both interfaces are different from the afRio1-ATP dimer interface that positions 
the helices of the C-lobe of one monomer in contact with both the N- and C-lobes of 
the second monomer almost completely occluding the active site.  
 
4.3e  Identification of RioK1 autophosphorylation sites. 
 Rio kinases that have been successfully expressed and purified thus far have 
serines as sites of autophosphorylation. One of the goals was to identify these 
autophosphorylation sites in RioK1 since there are no such reports to date. From the 
radioactivity gels the mutant S130A had diminished autophosphorylation activity as 
expected and the double mutant S130AS416A lacked any activity (Figure 4.15 A-B). 
This confirmed that serine 416 was the second autophosphorylation site.  Both Ser 
130 and Ser 416 are not found on the flexible loop, as is the case with afRio1 that has 
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4.3f RioK1 Affinity for Toyocamycin.  
Unbound RioK1 had a Tm of 41.1 ±1.1°C whereas RioK1 with toyocamycin 
bound had a Tm of 53.2 ±1.8°C corresponding to a 12.1°C shift (Figure 4.16). A 
similar Tm shift of 12.0°C is observed with afRio1 bound to toyocamycin. RioK1 with 
either sangivamycin or 7-methylinosine bound, had a Tm of 50.7°C, a 9.6°C increase 
and in the presence of ATP/Mg2+ the Tm was 50.0 ±1.2°C, a 8.9°C shift (Figure 4.16). 
These results confirmed that toyocamycin binds to RioK1 with a higher affinity than 
ATP/Mg2+, since it stabilizes RioK1 more than ATP/Mg2+. The same trend was 
observed with afRio1 supporting conservation between RioK1 and afRio1 in regards 
to affinity for toyocamycin. This similarity between afRio1 and RioK1 is somewhat 
expected considering that both proteins interact with ATP in an almost identical 
fashion and therefore RioK1 might have similar interactions with toyocamycin as 
those observed between afRio1 and toyocamycin. Obviously a crystal structure of 
RioK1 with toyocamycin bound would be more telling.  
  
4.3g Substrate inhibition by high concentrations of ATP.	  
 At high concentrations of ATP, autophosphoryation activity is diminished 
and is almost unmeasurable at 1800 µM and activity is only detectable at lower ATP 
concentrations as observed on the radioactive gels (Figure 4.17).  This is consistent 
with afRio1 studies that showed inhibition of afRio1 activity at high concentrations of 
ATP, suggesting that the two kinases may share a similar substrate inhibition 
mechanism that involves formation of oligomeric states that are promoted by high 
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concentrations of ATP. In this mechanism, inhibition occurs via modulation of 
binding sites in oligomers that are triggered by high concentrations of ATP.  
 
4.3h: Formation of Oligomers 
            Initial attempts to analyze oligomerization by sedimentation 
equilibrium resulted in aggregation of RioK1 and therefore size exclusion 
chromatography was used for analysis. Calibration proteins were used to generate a 
plot of Log of molecular weight as a function of elution volume was fit to linear 
regression using GraphPad prism. This plot was used to calculate the estimated 
molecular weight of the different RioK1 samples. The monomeric molecular weight 
of RioK1 is 45.13 kDa, the phosphorylated RioK1 had a calculated molecular weight 
of 70.3 kDa and eluted as a mixture of monomer and dimer (Figure 4.18). In the 
presence of ATP/Mg2+ RioK1 eluted mostly as a dimer with a calculated molecular 
weight of 104.3 kDa and in the presence of adenosine, RioK1 eluted as a tetramer 
with a calculated molecular weight of 179.1 kDa (Figure 4.18). Taken together this 
data shows that RioK1 does form higher order oligomers in the presence of ligands, 
consistent with observations made with afRio1. In addition, phosphorylation of 
RioK1 that occurs near the vicinity of two symmetry-related molecules, promotes 
some monomerization consistent with results from phosphorylated afRio1 (Figure 
4.13B). This suggests that both proteins can access multiple oligomeric states and 
could employ the same type of substrate inhibition mechanism and that 
phosphorylation may regulate catalytic activity. Steady state kinetic experiments of 
RioK1 would validate this hypothesis.   




A substantial amount of work went towards structural determination of RioK1 
from trying different constructs to applying limited proteolysis and surface entropy 
mutagenesis. Comparison between the crystal structure of RioK1-ATP complex and 
that of afRio1-ATP reveals that both complexes share similar interactions with ATP 
despite evolution. Differences between the two complexes include: a) the distance 
between the catalytic aspartate and the γ-phosphate of ATP, and b) crystal contacts/ 
interacting interfaces. Shifts are also observed on the N-lobe that houses the p-loop, 
the hinge region and metal binding loops of RioK1 relative to afRio1.  
The fact that both RioK1 and afRio1 share similar high binding affinities to 
toyocamycin may be an indication that both proteins bind to toyocamycin in a similar 
fashion and may maintain similar interactions. A co-crystal structure of RioK1 and 
toyocamycin would aid in characterizing the binding. In addition, toyocamycin can be 
used as a tool to identify RioK1 substrates in eukaryotic systems using methods 
described in chapter 2. Inhibition of RioK1 by toyocamycin can be carried out using 
kinase reactions similar to the ones used in the aracheal system. Other inhibition 
studies would be to determine the effect of toyocamycin on cell-cycle progression 
since eukaryotic Rio1 is implicated in the progression of cells from the G1 phase to 
the S phase and in the metaphase.  
This chapter presents the first eukaryotic structure of Rio1 that not only aided 
in identifying interactions of the protein with ATP but also potential biological 
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interfaces. It would be of interest to test how mutating residues involved in the 
interacting interfaces would affect dimerization that is observed in both crystallization 
and solution.  
 
 






        
	  





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
Figure 4.1: Preparative gels of RioK1 (106-494) purification. Expected molecular 
weight is 45.13 kDa. Lane M is the protein ladder A. Gel after first HisTrap column 
purification, lane 1 is the lysate and lane 2 is the flow-through after loading the 
protein onto the column. B. Gel after the second HisTrap column purification, lane 1 
is before histidine tag cleavage and lane 2 is after cleavage. C. Gel after size 
exclusion chromatography.   
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Figure 4.2: RioK1 (106-494) crystals. A. Needle-shaped crystals in PEGs Suite 
screen before optimization. B. RioK1 (106-494) optimized crystals that grew in  
0.2 M Calcium acetate and 20% PEG 3350. C. Se-Met RioK1 (106-494) crystals in 
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     Shell       Average Redundancy Per Shell
  Lower Upper      
  limit limit
  50.00  8.00             2.6
   8.00  6.36             2.8
   6.36  5.55             2.8
   5.55  5.05             2.8
   5.05  4.69             2.7
   4.69  4.41             2.6
   4.41  4.19             2.5
   4.19  4.01             2.4
   4.01  3.85             2.5
   3.85  3.72             2.4
   3.72  3.60             2.3
   3.60  3.50             2.4
  All hkl                 2.6
     Shell            I/Sigma in resolution shells:
  Lower Upper      % of of reflections with I / Sigma less than
  limit limit     0     1     2     3     5    10    20   >20  total
  50.00  8.00   0.4   1.2   3.2   5.1   7.2  15.1  33.2  66.4   99.6
   8.00  6.36   2.6   8.4  14.8  21.4  33.2  55.0  78.7  21.2   99.9
   6.36  5.55   6.9  18.2  29.5  40.6  55.5  75.3  92.6   7.3   99.9
   5.55  5.05   7.6  18.6  34.2  45.6  59.3  76.9  89.5  10.5  100.0
   5.05  4.69  10.3  22.9  34.4  45.8  60.6  78.7  92.0   8.0  100.0
   4.69  4.41  10.5  26.6  41.8  53.4  64.0  78.3  89.3   9.0   98.3
   4.41  4.19  14.1  32.4  47.7  56.7  67.7  81.2  88.7   5.2   93.9
   4.19  4.01  15.6  35.1  51.3  60.2  69.6  77.2  82.8   5.4   88.3
   4.01  3.85  17.1  34.3  46.4  53.0  59.8  67.4  73.3   4.1   77.3
   3.85  3.72  16.4  35.6  48.3  53.9  58.5  64.6  68.4   3.9   72.3
   3.72  3.60  15.5  32.8  46.4  51.5  56.9  61.4  64.1   2.4   66.6
   3.60  3.50  14.7  30.5  39.6  43.8  47.8  52.2  56.5   0.6   57.1
 All hkl       11.0  24.7  36.4  44.2  53.3  65.3  75.7  12.0   87.8
 Shell Lower Upper Average      Average     Norm. Linear Square
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac
      50.00   8.00   290.6     8.8     6.2  2.840  0.051  0.056
       8.00   6.36    76.8     5.0     4.7  1.871  0.089  0.078
       6.36   5.55    37.0     4.9     4.8  1.551  0.167  0.130
       5.55   5.05    41.8     5.8     5.7  1.682  0.178  0.133
       5.05   4.69    41.1     6.4     6.3  1.719  0.186  0.128
       4.69   4.41    49.4     7.3     7.1  1.849  0.164  0.117
       4.41   4.19    33.8     7.6     7.5  1.635  0.210  0.148
       4.19   4.01    34.4     8.4     8.3  1.738  0.201  0.131
       4.01   3.85    30.1     8.4     8.3  1.717  0.240  0.157
       3.85   3.72    30.2     8.9     8.8  2.494  0.253  0.157
       3.72   3.60    23.3     9.3     9.2  1.615  0.278  0.170
       3.60   3.50    16.5     9.3     9.2  1.821  0.443  0.359
  All reflections     63.4     7.3     6.9  1.869  0.134  0.088
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     Shell       Average Redundancy Per Shell
  Lower Upper      
  limit limit
  50.00  7.53             2.1
   7.53  5.98             2.0
   5.98  5.23             2.1
   5.23  4.75             2.0
   4.75  4.41             2.1
   4.41  4.15             2.1
   4.15  3.94             2.0
   3.94  3.77             2.0
   3.77  3.63             2.0
   3.63  3.50             1.9
  All hkl                 2.0
      Shell            I/Sigma in resolution shells:
  Lower Upper      % of of reflections with I / Sigma less than
  limit limit     0     1     2     3     5    10    20   >20  total
  50.00  7.53   0.9   2.8   5.3   8.7  16.2  32.9  63.7  32.8   96.5
   7.53  5.98   7.4  17.2  29.8  40.5  56.9  79.4  94.0   5.0   98.9
   5.98  5.23  12.7  28.8  45.3  59.5  75.6  89.7  97.2   1.3   98.6
   5.23  4.75  13.0  28.5  46.8  60.3  76.1  90.8  97.3   1.5   98.8
   4.75  4.41  14.1  31.0  49.1  62.7  75.2  88.4  96.2   2.6   98.7
   4.41  4.15  20.2  39.8  58.7  72.0  83.5  93.2  97.5   1.1   98.6
   4.15  3.94  21.6  44.5  65.6  77.3  86.4  93.3  97.8   0.9   98.7
   3.94  3.77  26.0  52.2  71.6  81.5  88.8  94.5  97.2   0.8   98.0
   3.77  3.63  31.9  58.5  76.5  85.4  91.1  94.5  96.9   0.6   97.5
   3.63  3.50  31.1  58.9  77.7  86.6  91.6  94.5  95.7   0.3   96.0
 All hkl       17.9  36.2  52.6  63.4  74.1  85.1  93.3   4.7   98.0
 Shell Lower Upper Average      Average     Norm. Linear Square
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac
      50.00   7.53    61.9     2.9     2.5  5.125  0.084  0.098
       7.53   5.98    15.3     2.1     2.0  2.687  0.178  0.130
       5.98   5.23     8.7     2.3     2.2  2.102  0.316  0.233
       5.23   4.75    10.4     2.7     2.7  2.206  0.324  0.171
       4.75   4.41    13.2     3.1     3.1  2.716  0.328  0.206
       4.41   4.15     8.5     3.4     3.3  2.327  0.490  0.328
       4.15   3.94     8.7     3.7     3.7  2.443  0.567  0.289
       3.94   3.77     7.2     4.1     4.0  2.839  0.707  0.701
       3.77   3.63     5.9     4.3     4.2  2.220  0.807  0.351
       3.63   3.50     4.1     4.5     4.4  1.842  0.950  0.384
  All reflections     14.3     3.3     3.2  2.667  0.280  0.186












Figure 4.3: Surface Entropy Mutagenesis (SER), RioK1_K269AE270A crystals.  
A. Crystals observed in Wizard III screen. B. Optimized crystals that grew in 24% 
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Figure 4.4: Limited Proteolysis assay. The gel represents trypsin proteolysis 
reaction. Lane M is the protein ladder. Lanes 1, 2, 3, 4 and 5 are samples after 0, 10, 
30, 60 minutes and 24 hours. The band at 25kDa is observed after 10 minutes and is 
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Figure 4.5: Mass spectrometry analysis for 25kDa fragment. Peptide 
identification from limited proteolysis assay. Peptide fragments in red were identified 
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Rio1 coverage for the second lower band. Amino acids identified: 
143-493 
     1 MDYRRLLMSR VVPGQFDDAD SSDSENRDLK TVKEKDDILF EDLQDNVNEN  
    51 GEGEIEDEEE EGYDDDDDDW DWDEGVGKLA KGYVWNGGSN PQANRQTSDS  
   101 SSAKMSTPAD KVLRKFENKI NLDKLNVTDS VINKVTEKSR QKEADMYRIK  
   151 DKADRATVEQ VLDPRTRMIL FKMLTRGIIT EINGCISTGK EANVYHASTA  
   201 NGESRAIKIY KTSILVFKDR DKYVSGEFRF RHGYCKGNPR KMVKTWAEKE  
   251 MRNLIRLNTA EIPCPEPIML RSHVLVMSFI GKDDMPAPLL KNVQLSESKA  
   301 RELYLQVIQY MRRMYQDARL VHADLSEFNM LYHGGGVYII DVSQSVEHDH  
   351 PHALEFLRKD CANVNDFFMR HSVAVMTVRE LFEFVTDPSI THENMDAYLS  
   401 KAMEIASQRT KEERSSQDHV DEEVFKRAYI PRTLNEVKNY ERDMDIIMKL  
   451 KEEDMAMNAQ QDNILYQTVT GLKKDLSGVQ KVPALLENQV EERTCSDSED  
   501 IGSSECSDTD SEEQGDHARP KKHTTDPDID KKERKKMVKE AQREKRKNKI  




Figure 4.6: Mass Spectrometry analysis for RioK1 (143-494). Peptide fragment 
















































Figure 4.7: Preparative gels of RioK1 (143-494) purification. Expected molecular 
weight is 40.89 kDa. Lane M is the protein ladder A. Gel after first HisTrap column 
purification, lane 1 is the lysate and lane 2 is the flow-through after loading the 
protein onto the column. B. Gel after the HisTrap nickel column purification, lane 1 is 
before histidine tag cleavage and lane 2 is after cleavage. C. Gel after size exclusion 
chromatography.  
A.                                                                 B.  
C. 






Eluted RioK1 (143-494) 






































Figure 4.8: RioK1 (143-494) crystals. A. Crystals observed in Wizard III screen 
before optimization. B. Crystals after optimization in 28% PEG 400, 0.1 M HEPES 
pH 7.5 and 0.2 M CaCl2. C. Se-Met RioK1 (143-494) optimized crystals that grew in 
28% PEG 400, 0.1M HEPES pH 7.5 and 0.2 M CaCl2. 
A.                                                                   B. 
C. 
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     Shell       Average Redundancy Per Shell
  Lower Upper      
  limit limit
  50.00  5.66             4.7
   5.66  4.50             4.8
   4.50  3.93             4.8
   3.93  3.57             4.8
   3.57  3.31             4.8
   3.31  3.12             4.8
   3.12  2.96             4.7
   2.96  2.83             4.1
   2.83  2.72             3.6
   2.72  2.63             3.5
  All hkl                 4.5
     Shell            I/Sigma in resolution shells:
  Lower Upper      % of of reflections with I / Sigma less than
  limit limit     0     1     2     3     5    10    20   >20  total
  50.00  5.66   0.1   0.2   0.4   0.8   1.5   9.6  99.5   0.0   99.5
   5.66  4.50   0.1   0.6   1.4   2.4   4.9  16.4 100.0   0.0  100.0
   4.50  3.93   0.3   1.8   3.7   5.0  10.9  24.3  99.0   1.0  100.0
   3.93  3.57   1.5   4.0   8.2  13.3  22.7  41.5  76.9  23.1  100.0
   3.57  3.31   3.1  10.1  18.9  28.8  41.9  61.3  80.0  20.0  100.0
   3.31  3.12   9.2  20.2  33.6  44.6  58.0  73.4  85.5  14.5  100.0
   3.12  2.96  14.3  32.6  49.7  59.2  68.7  80.6  90.0  10.0  100.0
   2.96  2.83  18.4  41.6  58.3  66.9  75.5  84.5  92.7   6.5   99.2
   2.83  2.72  19.6  44.1  59.5  65.7  70.4  77.3  83.4   5.6   89.0
   2.72  2.63  15.5  35.0  46.4  51.6  57.0  61.6  67.3   4.1   71.4
 All hkl        8.2  19.0  28.0  33.8  41.1  53.0  87.5   8.5   95.9
 Shell Lower Upper Average      Average     Norm. Linear Square
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac
      50.00   5.66   405.4    28.1     5.5  1.657  0.092  0.104
       5.66   4.50   176.0    12.1     3.1  1.312  0.103  0.114
       4.50   3.93   145.7     9.1     3.1  1.243  0.097  0.098
       3.93   3.57    95.1     4.9     2.8  1.227  0.091  0.077
       3.57   3.31    55.7     3.2     2.6  1.304  0.111  0.074
       3.31   3.12    25.6     2.6     2.4  1.246  0.189  0.127
       3.12   2.96    21.2     2.7     2.5  1.173  0.203  0.104
       2.96   2.83    12.3     2.8     2.6  1.005  0.261  0.152
       2.83   2.72    10.2     3.1     2.9  0.984  0.259  0.165
       2.72   2.63     9.6     3.1     2.9  0.999  0.253  0.167
  All reflections     99.1     7.3     3.0  1.241  0.106  0.102
     
	   101	  





     Shell       Average Redundancy Per Shell
  Lower Upper      
  limit limit
  50.00  6.14             5.4
   6.14  4.87             5.8
   4.87  4.26             5.9
   4.26  3.87             6.0
   3.87  3.59             6.0
   3.59  3.38             6.0
   3.38  3.21             6.1
   3.21  3.07             5.7
   3.07  2.95             5.3
   2.95  2.85             5.0
  All hkl                 5.7
     Shell            I/Sigma in resolution shells:
  Lower Upper      % of of reflections with I / Sigma less than
  limit limit     0     1     2     3     5    10    20   >20  total
  50.00  6.14   1.0   2.2   2.6   2.9   4.0  13.1  54.2  44.2   98.4
   6.14  4.87   1.1   2.1   4.3   6.0   9.9  23.7  64.0  35.9   99.9
   4.87  4.26   2.3   5.3   8.9  12.2  19.0  33.1  63.1  36.9  100.0
   4.26  3.87   4.6   8.9  15.1  21.6  33.2  48.9  74.6  25.4  100.0
   3.87  3.59   8.1  18.9  29.6  37.7  52.2  70.1  86.4  13.6  100.0
   3.59  3.38  15.1  32.1  47.4  58.4  68.8  79.6  90.3   9.7  100.0
   3.38  3.21  22.0  44.0  60.1  69.0  78.1  86.1  93.8   6.0   99.8
   3.21  3.07  28.0  51.4  68.0  74.9  81.4  88.4  95.3   2.6   97.9
   3.07  2.95  27.4  51.6  64.9  72.3  77.2  83.5  88.3   3.1   91.4
   2.95  2.85  26.9  48.5  61.0  67.1  72.0  77.7  81.3   1.5   82.8
 All hkl       13.4  26.0  35.5  41.5  48.8  59.7  78.8  18.4   97.1
 Shell Lower Upper Average      Average     Norm. Linear Square
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac
      50.00   6.14   714.6    34.6    11.6  1.179  0.084  0.107
       6.14   4.87   186.8     9.1     3.9  1.198  0.083  0.094
       4.87   4.26   199.2     8.7     4.2  1.083  0.072  0.074
       4.26   3.87   144.2     6.9     4.2  1.152  0.077  0.062
       3.87   3.59    86.6     5.5     4.1  1.174  0.111  0.087
       3.59   3.38    48.3     4.8     4.1  1.435  0.170  0.098
       3.38   3.21    25.1     4.4     4.0  1.423  0.283  0.166
       3.21   3.07    14.2     4.5     4.3  1.431  0.435  0.243
       3.07   2.95    16.0     5.0     4.8  1.548  0.362  0.187
       2.95   2.85     8.8     5.3     5.2  1.346  0.543  0.347
  All reflections    153.9     9.2     5.1  1.288  0.102  0.100
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Data collection  
     Space group P32 
     Cell dimensions  
           a, b, c (Å) 78.81, 78.81, 110.57 
           α, β, γ (°) 90, 90, 120 
     Molecules/Asym. unit   2 
      Wavelength (Å) 0.97919 
     Resolution (Å) 2.63 
     Rsym (last shell) 10.6 (25.3) 
     I/σI 13.6 (3.1) 
     Completeness (%) 95.9 (71.4) 




     Resolution (Å) 68.25-2.63 
     Rwork/Rfree (%) 22.8/26.6 
     Mean B-factors (Å)2   
     
 42.96 
     RMS deviations  
           Bond lengths (Å) 0.0168 
           Bond angles (°) 1.8768 
     Ramachandran plot  
           Favored 94.6 
        Additional Allowed  5.4 
           Disallowed    0.0 
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Figure 4.9: RioK1 (143-494) overall structure. RioK1 (143-494) overall structure 
characterized by a β-sheet on the N-lobe along with a sub-family specific helix, αR, 
and a α-helical C-lobe. The helices are labeled according to afRio1 structure and the 










Figure 4.10: RioK1 (143-494)-ATP/Mg2+ alignment of the two molecules per 




























Figure 4.11: Alignment of RioK1 and afRio1. RioK1 structure is in yellow and 
afRio1 is red. A. Overall alignment of RioK1 and afRio1 (PDB ID: IZP9). B. 
Alignment of the active site of RioK1 and afRio1. Shifts are observed in the N-lobe 
and the metal-binding loop.  
A. 
B. 











Figure 4.12: RioK1 (143-494)-ATP/Mg2+ interactions. A. Shows hydrophobic  
interactions. B. Shows hydrogen bonds as black dashed lines. Spheres in green are 




























Figure 4.13: RioK1 potential interacting interfaces. A. Interface between two   
molecules in the asymmetric unit. Monomer A is in blue and monomer B is in yellow. 
B. Interface between symmetry related molecules, molecule A is in yellow and 
molecule B is in magenta. The autophosphorylation site, ser 416 (in red) is found in 



















































Figure 4.14: RioK1 (106-494) Electrospray Ionization Spectrum. Three peaks are 
observed corresponding to the expected molecular weight, 45126.18 Daltons, singly 
phosphorylated RioK1 (106-494), 45203.69 Daltons and doubly phosphorylated 






20090302MW11 #83-103 RT: 10.09-11.77 AV: 21 NL: 8.43E4
T: FTMS + p ESI Full ms [450.00-2000.00]







































































20090302MW11_XT_00001_M__090305230834 #1 RT: 1.00 AV: 1 NL: 2.05E4
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Figure 4.15: Identifying RioK1 autophosphorylation sites. A. Denaturing gel 
showing autophosphorylation activity. Lane 1 is wild-type protein, lane 2 is the 
mutant S130A, lane 3 is the mutant S415A, lane 4 is the mutant S416A, lane 5 is the 
mutant S130AS415A and lane 6 is S130AS416A. B. Graph representing percent of 
autophosphorylation activity. From both the gel and graph it’s clear that the two sites 
are Ser 130 and Ser 416. 
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Figure 4.16: RioK1 Thermoflour assay. Toyocamycin has the biggest Tm shift of 
12.1°C comparable to afRio1 studies. Toyocamycin binds with a higher affinity and 












Figure 4.17: Substrate inhibition assay. At high concentrations of ATP, RioK1 
autophosphorylation activity is diminished whereas at low concentrations of ATP 
such as 0.9 µM, activity is observed.  








Figure 4.18: RioK1 size exclusion chromatography data.  Oligomers are observed 
in the presence of adenosine and ATP. A. Shows the size exclusion chromatogram. B. 
Table with calculated molecular weight and corresponding oligomeric state.  
 
 
Sample Calculated  
MW (kDa) 
Oligomer 
Phosphorylated RioK1 70.3 Monomer-Dimer 
RioK1+ATP 104.3 Dimer 
RioK1+Adenosine 179.1 Tetramer 
A. 
B. 
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Crystal packing analysis of afRio1 structure in the absence of ATP revealed 
contact between two symmetry-related molecules via the flexible loop of one 
molecule and the active site of the second molecule (Figure 5.1). This interaction 
positions the autophosphorylation site, serine 108, of one molecule close to the active 
site of the second molecule and involves several conserved residues that do not 
appear to be involved in ATP binding based on the crystal structure of afRio1 with 
ATP bound (Figure 5.1). These residues are conserved among Rio proteins and across 
species suggesting their involvement in a significant role, possibly peptide or protein 
substrate binding, recognition and interaction. This chapter focuses on determining 
how conserved residues found near the active site affect afRio1 autophosphorylation 
and kinase activity. The following residues Lys 59, Glu 60, Arg 83, and Tyr 200 were 
mutated and tested for activity. 	  
 
5.2 Experimental   
5.2 a Mutagenesis, expression and purification of afRio1 mutants. 
Site-directed mutagenesis was carried out using QuikChange II kit (Agilent) 
according to manufacturer’s instructions. AfRio1 mutants, K59A, E60A, R83A, and 
Y200D were expressed and purified following the same protocol as wild-type afRio1 
with three modifications. After lysis, the lysate was heated at 68°C instead of 75°C 
for 15 minutes to denature E.coli proteins, the N-terminal histidine tag was not 
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cleaved and ion exchange was the final purification step instead of size exclusion 
chromatography.  
After the first HisTrap column purification, all mutants were dialyzed against 
a buffer containing 50 mM Tris pH 8.0, 200 mM NaCl and 0.2% β-mercaptoethanol 
followed by dilution with different buffer containing 50 mM Tris pH 8.0 and 0.2% β-
mercaptoethanol for a final salt concentration of 100 mM NaCl. All mutants were 
loaded onto an ion exchange column, the Q column (GE healthcare) at rate of 1.0 
mL/min and subjected to a salt gradient of 100 mM NaCl to 1 M NaCl. AfRio1 
mutants eluted between 200 mM and 300 mM NaCl and all purification steps were 
monitored by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE 
gel) for purity (Figure 5.2).  
 
5.2b Autophosphorylation and Kinase activity assays.  
For autophosphorylation assays, 5 µg of purified mutants, K59A, E60A, 
R83A, Y200D and wild-type afRio1 were added to a 30 µl reaction containing 50 
mM Tris pH 8.0, 50 mM NaCl and 2 mM MgCl2. 5 µCi of γ-32P labeled ATP was 
added to the reactions and incubated at 37°C for 1 hour. For assays used to test kinase 
activity, 0.5 µg instead of 5 µg of purified protein was added to the reactions along 
with 10 µg of myelin basic protein (MBP), a general kinase substrate. All reactions 
were carried out in triplicates, stopped by adding 8 µl of SDS loading dye to denature 
the protein. The reaction mixtures were ran on NuPAGE®4-12% Bis-Tris denaturing 
gels (Invitrogen) at 150V for 45 minutes to separate the protein from γ-32P labeled 
ATP. Gels were dried and exposed on a phosphoimager screen for 15 hours followed 
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by quantification using the software ImageQuant (Molecular Dimensions) to 
determine autophosphorylation and kinase activity (Figure 5.3). 
 
5.3: Results  
AfRio1 E60A mutant had the least amount of autophosphorylation and kinase 
activity whereas afRio1 K59A had the most autophosphorylation activity but a 
diminished kinase activity, second to afRio1 E60A (Figure 5.3 and 5.4). Glu 60 and 
Lys 59 are both found on the nucleotide-binding loop (p-loop) of Rio kinases and 
though they are found near the active site, they do not participate in binding 
interactions with ATP. The autophosphorylation results suggest that Lys 59 is not 
vital in phosphorylating afRio1 since its mutation has no effect on autphosphorylation 
activity. However, Lys 59 seems to be important in phosphorylating protein 
substrates such as MBP as per kinase assays. On the other hand, the results clearly 
indicate the importance of Glu 60 in both autophosphorylation and phosphorylation 
of protein substrates.  
AfRio1 Y200D mutant had both diminished autophosphorylaytion and kinase 
activities with more effect on autophosphorylation (Figure 5.3 and 5.4). Tyrosine 200 
that is found on the catalytic loop is either a tyrosine or a phenylalanine in RIO 
kinases. AfRio1 Y200D’s diminished catalytic activity is not surprising for a 
mutation on a residue that is found on the catalytic loop. Finally Arg 83, that is either 
an arginine or a lysine in Rio1 kinases, does not affect autophosphorylation or kinase 
activity to a large extent, indicating that the residue, though conserved, might not be 
important for protein substrate recognition, interactions or activity. 
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5.4 Summary 
 This chapter identifies conserved residues, Lys 59, Glu 60 and Y200 to be 
vital for afRio1 activity. Though the residues are not involved in ATP binding, they 
do seem to have another vital role, possibly protein or peptide substrate binding, 
recognition and interaction. Experiments with Rio1-specific substrates, which have 
not yet been identified, as well as crystal structures of a mutant-substrate complex 
would aid in identifying with certainty the role of these residues.  It would also be of 
interest to see how the mutants affect the oligomeric state of afRio1, which in 











	   117	  
 
 
Figure 5.1: Interface between two symmetry-related molecules of afRio1 without 
ATP bound. Contact is between the flexible loop of one molecule (magenta) and the 
active site of the second molecule (green). Conserved residues near the active site are 
that were mutated are labeled on one molecule (green). Residual adenosine, labeled 
Ade, is observed in the active site. 
 
 





Figure 5.2: SDS preparative gels of afRio1 mutants after ion exchange 
purification. Lane M in all gels is the protein ladder. A. AfRio1 K59A mutant. B. 
AfRio1 E60A mutant. C.  AfRio1 R83A mutant, Lane 1 is the lysate sample and Lane 
2 is uninduced sample. D. AfRio1 Y200D mutant. 
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Figure 5.3: Autophosphorylation assay. A. Preparative gel showing 
autophosphorylation activity. All reactions were done in triplicates; E60A mutant has 
the least activity whereas K59A has the most activity. Lane 1 is wild-type afRio1 
reaction, lane 2 is K59A reaction, lane 3 is E60A reaction, lane 4 is R83A reaction 



























Figure 5.4: Kinase assay used to determine activity by amount of myelin basic 
protein (MBP) phosphorylation. A. Preparative gel showing phosphorylation of 
MBP. All reactions were done in triplicates; E60A mutant has the least activity 
whereas the wild-type has the most activity. Lane 1 is wild-type afRio1 reaction, lane 
2 is K59A reaction, lane 3 is E60A reaction, lane 4 is R83A reaction and lane 5 is 
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Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium 
tuberculosis (Mtb) that affects the respiratory system. In 1993, the World Health 
Organization (WHO) declared tuberculosis to be a global health emergence and 
remains to be one of the world’s major causes of illness and death (101).  A third of 
the world’s population is infected with M. tuberculosis and most infections affect 
people in resource-poor settings. For instance 90% of new TB cases and deaths occur 
in developing countries due to poor health systems, treatment barriers (unreliable 
drug supply or patients not completing treatment) and limited resources for disease 
detection. In addition, the emergence of drug resistant TB as well as TB and HIV co-
infections pose a threat to global control of the disease (102). In 2008, of the 
estimated 1.8 million people who died from TB, 500,000 were HIV-positive making 
it the leading cause of death among people living with HIV (102). TB treatment can 
also take a long time and be expensive especially due to drug-resistant TB of which 
there are two forms, multidrug-resistant TB (MDR-TB) and extensively drug-resistant 
TB (XDR-TB) (103). MDR-TB is resistant to standard first line drugs such as 
rifampicin and XDR-TB is resistant to both first and second line drugs such as 
amikacin(102) (104). The severity of this disease necessitates a better understanding 
of Mtb’s pathogenic mechanism with the aim of developing new therapeutics to 
combat TB.  
Mycobacterium tuberculosis (Mtb) was first discovered in 1882 by Robert 
Koch and is one of the 85 species in the mycobacterium genus. Mtb has a thick cell 
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wall that is covalently linked by a layer of branched-chain fatty acids known as 
mycolic acids. This provides a protective, hydrophobic waxy coat known as the 
mycomembrane. Mtb requires high levels of oxygen and thrives well in the human 
lungs. Upon Mtb infection, a phagosome is formed via phagocytosis of the bacterium 
by macrophages. The phagosome undergoes maturation by first fusing with various 
endosomes via the endocytic pathway followed by fusion with lysosomes to form 
phagolysosomes (105-107). During phagolysosome formation, degradative enzymes 
that destroy invading pathogens are released and the pH drops to about 4.5, an 
environment that is not conducive for Mtb survival(108). Phagolysosome formation is 
one of the multiple antimicrobial responses that the host cell employs to limit the 
growth of infection (109).  
Survival of Mtb in macrophages is critical to the virulence and pathogenesis of 
the bacterium. One survival response that Mtb utilizes is inhibition of phagosome 
maturation by preventing acidification of the phagosome by lysosomes that have a pH 
of about 4.5. The phagosome is arrested in the endocytic pathway under a conducive 
pH of about 6.4 and phagolysosomes are not formed (110)106). The phagosome 
inhibition mechanism is not well understood but studies do show the involvement of a 
specialized secretion pathway known as ESX-1(111-113). This secretion pathway 
aids Mtb manipulate its environment by delivering virulence factors during infection.  
The ESX-1 secretion system also known as Type VII secretion system, has 
several virulence proteins that are substrates including culture filtrate protein-10 
(CFP-10), early secretory antigenic target-6 (ESAT-6) and ESX-1 substrate protein B 
(EspB) among others (113, 114). The ESX-1 secretion system is encoded for by a 
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chromosomal region RD1 (Region of Difference-1) comprised of nine genes 
(Rv3871-Rv3879c) and its surrounding region, together known as extRD1 (extended 
region of difference-1) (111, 113, 115, 116). RD1 was identified via comparative 
studies of complete genomes of various mycobacterial species. For instance the less 
virulent species, Mycobacterium bovis Bacille Calmette-Guérin (BCG) lacks this 
chromosomal region that is present in more virulent species such as Mtb and M. 
marinum (117, 118). M. marinum is genetically closely related to Mtb and causes TB-
like diseases in its natural hosts (fish and frogs). M. marinum is therefore used in 
understanding Mtb pathogenesis. ESX-1 also has core components that include 
ATPase members (Rv3870, Rv 3871, Rv 3876), a transmembrane protein (Rv 3877) 
and MycP1, a substilin-like serine protease (119) (Figure 6.1).  
ESX-1 secretion has been implicated in inhibition of phagosome maturation, 
escape of Mtb from endocytic membrane, apoptosis of macrophages, and formation 
of pores in mycobaterial phagosomes allowing for the spread of bacteria (115, 120-
123). ESX-1 is unique in that substrate secretion is mutually dependent (124).  For 
instance it has been shown that secretion of CFP-10, ESAT-6 and EspB is co-
dependent and ESAT-6 interacts with the C-terminus of EspB(113). Studies also 
show that CFP-10 and ESAT-6 form a 1:1 heterodimer complex that interacts with 
the ATPase component Rv3871 (114). In addition, the N-terminus of EspB interacts 
with the C-terminus of Rv3879c, which then interacts with Rv3871 delivering EspB 
to the Rv3871-CFP-10/ESAT-6 secretory machine (114). In this role, Rv3879c is 
hypothesized to be a cytosolic chaperone and these interactions are necessary for 
secretion.  Once EspB is secreted to the periplasmic space, the protease MycP1 that is 
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localized near the cell membrane cleaves EspB at two sites, Ala 392 and Pro 332 on 
the C-terminus (119). EspB has a third cleavage site but the protease responsible has 
not yet been identified. While EspB’s C-terminus is necessary for interaction and 
secretion of CFP-10/ESAT-6 complex, it is not required for EspB secretion. This is 
supported by studies that show an EspB fragment with the C-terminus truncated is 
secreted by ESX-1(113, 114).  Further evidence for EspB’s C-terminus involvement 
in secretion is found in a system that has a MycP1 mutant (MycP1 S332A) whose 
protease activity is abolished. This mutant is not able to cleave EspB and 
consequently ESX-1 secretion is upregulated as EspB’s C-terminus is available for 
interaction and secretion of ESX-1 substrates (119). 
ESX-1 secretion pathway is not fully understood and some unknowns that 
interest my current lab include: a) the molecular structure of EspB  
b) EspB oligomeric state and how this relates to different cellular environments that 
Mtb encounters, c) interaction of EspB with ESAT-6 and Rv3879c, and d) the role of 
EspB proteolytic fragments, their oligomeric states, their interactions and functions in 
different cellular compartments. This chapter describes the work that went towards 
structural determination of EspB and presents the first crystal structure of EspB along 
with structural analysis.  
 
6.2 Experimental  
 
6.2a Expression of Se-Met EspB 1-292 and EspB 1-346 
 
Two constructs of EspB from M.Marinum, EspB residues 1-292 and EspB 
residues 1-346 were expressed, purified and crystallized. These constructs were 
designed based on previous work that had shown degradation of full-length EspB 
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during purification, mass spectrometry analysis by a former collaborator, Dr. Gao, 
showing cleavage at Leu 346 and limited proteolysis results that identified EspB (1-
292) as a stable fragment. EspB (1-292) and EspB (1-346) plasmids with N-terminal 
histidine tags were transformed to Rosetta(DE3) pLysS E.coli cells (Novagen). 
EspB (1-292) was expressed in 1 L of seleno-methionine minimal media (Shanghai, 
Medilon Inc) with 34 µg/mL chloramphenicol and 100 µg/mL ampicillin, to generate 
Se-Met protein. The cells were grown at 37°C while shaking at 250 rpm. Once the 
OD600 reached 1.2, 1 mM of Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
added to the media for induction and expression proceeded at 18°C for 24 hours. The 
cells were centrifuged at 5,000 rpm and 4°C for 20 minutes using a Sorvall centrifuge 
(Dupont) with a SLC 4000 rotor. The bacterial pellet was stored at -80°C. EspB (1-
346) was expressed in 2 L of LB media following the same expression procedure as 
EspB (1-292). The strategy was to solve the structure of EspB (1-292) by single 
anomalous dispersion (SAD) phasing and then use this model for molecular 
replacement to solve EspB (1-346).  
 
6.2b Purification of Se-Met EspB (1-292) and EspB (1-346) 
The frozen bacterial cell pellets were resuspended in lysis buffer containing  
50 mM Tris pH 8.0, 200 mM NaCl, 0.05% β-mercaptoethanol, 10% glycerol and one 
tablet of protease inhibitor. The resuspended bacterial cell pellets were lyzed using a 
French press and the lysate was centrifuged at 4°C and 18,000 rpm for 40 minutes 
using a Beckman Coulter ultracentrifuge with a 45 Ti rotor. The supernatant was 
filtered and imidazole added for a final concentration of 20 mM. This supernatant was 
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loaded onto a pre-equilibrated 5mL HisTrapHP column (GE healthcare) attached to 
a Fast Protein Liquid Chromatography (FPLC) system at a flowrate of 2.0 mL/min 
and washed with 10 column volumes of lysis buffer to remove any unbound protein. 
Bound protein was subjected to an imidazole gradient of 20 mM to 250 mM and  
Se-Met EspB (1-292) eluted between 100 mM and 150 mM imidazole whereas EspB 
(1-346) eluted between 120 mM and 160 mM imidazole. Partially purified fractions 
were pooled together and transferred to a dialysis membrane to which 1 mg/mL of 
Tobacco etch virus (TEV) protease was added to cleave the histidine tag. Se-Met 
EspB (1-292) was dialyzed overnight at 4°C against 20 mM Tris pH 8.0, 50 mM 
NaCl, 0.05% β-mercaptoethanol and 10% glycerol whereas EspB (1-346) was 
dialyzed against the lysis buffer. After cleavage both proteins were loaded onto a pre-
equilibrated 5mL HisTrapHP column (GE healthcare) and Se-Met EspB (1-292) 
washed with the same buffer used for dialysis whereas EspB (1-346) was washed 
with the lysis buffer. Both cleaved proteins were further purified by size exclusion 
chromatography using a Superdex200 column (GE healthcare) equilibrated in 10 
mM HEPES, 50 mM NaCl and 0.05% β-mercaptoethanol at pH 7.5 for Se-Met EspB 
(1-292) and pH 8.0 for EspB (1-346). All purification steps were monitored by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) for purity 
(Figure 6.2).  
 
6.2c Crystallization of Se-Met EspB (1-292) and EspB (1-346) 
Purified Se-Met EspB (1-292) was concentrated to 22 mg/mL and EspB  
(1-346) to 39 mg/mL. Both proteins were subjected to robotic sparse matrix screening 
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using Phoenix Liquid Handing System (Art Robbins). Commercially available matrix 
screens, Index (Hampton), Cyros (Qiagen), PEGs suite (Qiagen), Wizard I, II and III 
(Emerald Biosystems) were used for initial crystal screening in 96 well plates with 
three different protein to well solution ratios (1:2, 1:1, 2:1). Crystals observed during 
initial screening were optimized to generate diffraction quality crystals. For Se-Met 
(1-292), three different crystal forms, hexagonal, rectangular and diamond-shaped, 
were observed in Index, Wizard I and III respectively (Figure 6.3). The diamond-
shaped crystals grew in 1.2 M NaH2PO4, 0.8 M K2HPO4, 0.1 M CAPS pH 10.5, 0.2 
M Li2SO4 and optimized crystals were observed with pH 8.5 and 9.5. The 
rectangular-shaped crystals grew in 0.2 M MgCl2.2H2O, 25% PEG 3350, 0.1 M Tris 
pH 8.5 and after optimization additional crystals were observed in pH 6.5 and 7.5. 
Finally the hexagonal-shaped crystals grew in 20% PEG 3350, 0.2 M Magnesium 
formate and after optimization crystals were observed in pH 6.5, 7.5, 8.5 and 9.5. 
Diffraction quality crystals were flash frozen in their respective well conditions with 
20 % (v/v) ethylene glycol as the cryoprotectant. It was clear that crystals grew in 
different pH conditions, including pH 6.5 that mimics the intracellular pH of a 
phagosome. Consequently an attempt was made to determine the crystal structure of 
different crystal forms as well as crystals from different pH conditions. The goal was 
to determine whether different pH ranges and crystal forms resulted in different 
protein conformations/overall structure. 
EspB (1-346) crystals were observed in Wizard I and grew in 0.2 M NaCl, 
25% PEG 3350 and 0.1 M Bis Tris pH 5.5. The rod-shaped crystals were optimized 
and diffraction quality crystals were observed in pH 7.5 (Figure 6.4). As with  
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EspB (1-292), the crystals were flash frozen with 20% (v/v) glycerol as the cryo-
protectant and shipped to Argonne, IL. 
 
6.2d Data collection and structure determination  
 
 
Data was collected at 100K at the NE-CAT beamline at the Advanced Photon 
Source (APS), Argonne, IL, USA. The diamond-shaped crystals diffracted to 2.5 Å 
whereas the hexagonal-shaped crystals diffracted to 6.0 Å. Data was indexed, 
integrated and scaled using HKL2000 package program (71). The better diffracting 
crystals belonged to P21 space group and the unit cell dimensions were a= 173.45 Å, 
b= 81.70 Å, c= 267.47 Å and α=90.000, β=108.770, γ=90.000. The overall redundancy 
was 3.7 with 99.5% data completion and an overall Rsymm of 14.2% (Table 6.1). The 
structure was solved using an automated experimental phasing program, Autosol, that 
is part of PHENIX (93). Autosol found 144 heavy atoms sites using hybrid 
substructure search (HYSS). Experimental phases were calculated using Phaser and 
improved by density modification using RESOLVE (90-92). After obtaining density-
modified phases the program carries out a round of model building and refinement. 
The initial model was first subjected to two rounds of model building using 
AUTOBUILD that is part of PHENIX (97-100). Subsequent rounds of model 
building were carried out in COOT accompanied by several rounds of refinement 
using phenix.refine (75, 76). Waters were added to the structure using PHENIX and 
the model has a Rwork/Rfree of 20.6/24.6 (Table 6.2). The refined crystal structure had 
sixteen molecules per asymmetric unit (ASU) (Figure 6.5).  
The hexagonal-shaped crystals that diffracted to 6.0 Å belonged to P3 space 
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group. The unit cell dimensions were a= 123.55 Å, b= 123.55 Å, c= 164.98 Å and 
α=90.000, β=90.000, γ=120.000 with an overall redundancy of 4.6, an overall Rsymm of 
17.0% and 99.7% data completion (Table 6.4). EspB (1-346) crystals diffracted to 
6.75 Å and belonged to P222 space group with cell dimensions a= 91.89 Å, b= 93.28 
Å, c= 156.09 Å and α=90.000, β=90.000, γ=90.000. The overall redundancy was 4.0, 
with an overall Rsymm of 13.6% and 99.5% data completion (Table 6.5). Attempts 
were made to solve the low-resolution structures by molecular replacement using 
MOLREP that’s part of CCP4i. Se-Met EspB (1-292) that diffracted to 2.5 Å was 
used as a search model (73). 
 
 
6.3 Structural analysis of Se-Met EspB (1-292) 
 
6.3 a Overall Structure of EspB (1-292) 
EspB has no known structural or sequence homologs of known function and 
this chapter presents the first crystal structure of EspB. Se-Met EspB (1-292) crystal 
structure has 16 monomers in the asymmetric unit (molecules A-P) arranged into a set 
of four homotetramers. Two sets of these tetramers (tetramers 1 and 3; tetramers 2 
and 4) that are arranged parallel to each other (Figure 6.5). Contact is observed 
between the C-terminal loop of one tetramer and the C-lobe helices of the adjacent 
tetramer (Figure 6.5). For instance in tetramer 2, the C-terminal loop of one monomer 
within that tetramer contacts the C-lobe helices of a monomer within tetramer 1, 
similar contacts are observed between tetramers 2 and 3 as well as 3 and 4 (Figure 
6.5). One homotetramer has two monomers (monomers A and B and monomers C 
and D) arranged anti-parallel to each other creating an interacting interface and a 
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central helix bundle (Figure 6.6). Contact is also observed between the C-lobe helices 
of two monomers within the tetramer. For instance monomer A interacts with 
monomer D and monomer B interacts with C via the C-lobe helices (Figure 6.6). 
Each monomer is largely alpha helical (α1-α7) and is roughly shaped like a cylinder, 
103.6 Å in length with a circular cross of 16.1 Å in diameter (Figure 6.7). The 
monomers have regions on the N- and C- terminus that lack electron density due to 
disorder and flexibility on these ends. All monomers, with the exception of monomer 
A and J, lack electron density for residues 1-8 on the N-terminus whereas eight 
monomers (monomer E, G, H, I, J, M, N and O) lack density for residues 287-292 on 
the C-terminus. In addition, all monomers lack density for residues 83-114. The 
overall monomeric structure also has an interesting feature on the C-terminus that is 
characterized by a polyproline region (residues 286-288), and of the last twenty-two 
C-terminal residues, ten are prolines.  
Comparison of EspB (1-292) crystal structures that crystallized at different pH 
conditions, 8.5 and 9.5, and EspB (1-346) had the same overall structure and 
arrangement of tetramers. This conserved arrangement of tetramers suggests a 
possible biological significance. 
 
6.3b Interfaces  
 The arrangement and position of monomers within a tetramer reveals 
two intra-tetramer interfaces, one between the anti-parallel monomers (monomer A 
and B) and another between the C-lobes helices of two monomers (monomer B and 
C) (Figure 6.8A). PDBe PISA (protein interfaces, surfaces and assemblies) server was 
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used to analyze these interfaces as well as calculate the buried surface area. The 
interface between the C-lobe helices involves α4, α5 and α6 of both monomers and 
has the largest calculated surface area of 1040.9 Å2. This interface is characterized by 
hydrophobic contact between Val 150 on monomer D and Val 230 on A, Leu 217 of 
monomer D and Ala 227 on A, and Leu 226 on D with Leu 217 on A. Hydrogen bond 
interactions involving side chains are observed between; Asp 154 on D and Lys 237 
on A; Arg 221 on D and Asp 228 on A; two hydrogen bonds between the side chains 
of Arg 220 on D and Glu 141 on A; Glu 141 on D and Arg 220 on A; Lys 237 on D 
and Asn 151 on A; Arg 234 on D and Gln 214 on A; Glu 233 on D and Thr 147 on A; 
two hydrogen bonds between side chains of Glu 231 on D and Arg 221 on A; a water-
mediated interaction between Arg 221 of D and Thr 225 of A; and finally between 
Glu 214 on D and Arg 234 on D (Figure 6.8 A). 
 The second interface involving the anti-parallel monomers is characterized by 
interactions between the N-lobe of one monomer and a helical C-lobe (α6) on the 
second monomer. Interactions are also observed between an N-lobe helix (α2) on one 
monomer and α3 found between the N and C-lobe on the second monomer (Figure 
6.8B). This interface has a calculated buried surface area of 856.8 Å2 and has 
hydrophobic contact between Val 32 on monomer A and Phe 130 on monomer B. 
Hydrogen interactions are observed between the carboxylate side chain of Glu 233 on 
monomer A and Thr 30 on B; amine side chain of Lys 139 on monomer A and the 
peptidyl carbonyl oxygen of Glu 47 on B; amine side chain of Lys 134 on A and the 
peptidyl carbonyl oxygen of Thr 30 on B; Glu 47 on A with both Lys 139 and Lys 
134 on B; Glu 47 on monomer A also has a water-mediated interaction with the 
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peptidyl carbonyl oxygen of Gly 126 on B; Asn 43 of A has two interactions, one 
with Thr 40 on B and the other with the peptidyl carbonyl oxygen of Glu 38 on B; 
hydroxyl group on Thr 40 on A with amine group of Asn 43 on B; and finally Thr 30 
of monomer A  has two interactions, one via the peptidyl carbonyl oxygen with the 
side chain of Lys 134 on B and another via the hydroxyl group of Thr and the 
carboxylate side chain of Glu 233 on  B (Figure 6.8 B). 
 PISA analysis suggests that intra-tetramer interactions have a more 
significant role in complex formation and the contact between tetramers involving the 
C terminal of one tetramer and the C-lobe helix, α7, of the adjacent tetramer, is 
characterized by few residues and has a buried calculated surface area of 410 Å2. 
Mutational studies and oligomeric state analysis would aid in identifying biological 
significant interfaces and effect on structure as well as function.  
 
6.4 Conclusion 
 This chapter presents the first crystal structure of EspB providing objectives 
for biological studies such as mutational studies of residues found on intra-tetramer 
interfaces, oligomeric state analysis of these mutants as well as studying oligomeric 

























Figure 6.1 EspB secretion model. Core components Rv3870, Rv3871, Rv3879c and 
Rv3877 and some of the substrates, CFP-10, ESAT-6 and EspB involved in ESX-1 
secretion are shown. EspB interacts with Rv3879c and is delivered to the Rv3871 
secretion machinery where EspB interacts with ESAT. After secretion, EspB is 













Figure 6.2: Preparative gels after size exclusion chromatography. Lane M in all 
gels is the protein ladder. A. Gel for Se-Met EspB (1-292) with an expected 
molecular weight of 31.8kDa. B. Gel for EspB (1-346) with an expected molecular 
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Figure 6.3: Se-Met EspB (1-292) crystals. A. Diamond-shaped crystals at pH 8.5 
that diffracted to 2.5Å. B. Hexagonal-shaped crystals at pH 6.5 that diffracted to 6.0 
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      Shell       Average Redundancy Per Shell
  Lower Upper      
  limit limit
  50.00  5.38             3.9
   5.38  4.27             3.8
   4.27  3.73             3.9
   3.73  3.39             3.9
   3.39  3.15             3.9
   3.15  2.96             3.9
   2.96  2.82             3.8
   2.82  2.69             3.8
   2.69  2.59             3.5
   2.59  2.50             3.0
  All hkl                 3.7
     Shell            I/Sigma in resolution shells:
  Lower Upper      % of of reflections with I / Sigma less than
  limit limit     0     1     2     3     5    10    20   >20  total
  50.00  5.38   0.2   0.9   2.0   3.2   5.9  16.0  99.9   0.0   99.9
   5.38  4.27   0.6   1.7   3.4   5.2   9.3  24.2 100.0   0.0  100.0
   4.27  3.73   1.3   3.2   5.7   8.4  14.3  33.4 100.0   0.0  100.0
   3.73  3.39   2.2   5.6  10.1  14.8  23.8  48.4  96.8   3.2  100.0
   3.39  3.15   3.9  10.0  17.9  25.4  39.5  67.9  98.3   1.7  100.0
   3.15  2.96   6.6  16.6  28.3  39.0  56.3  82.8  98.8   1.2  100.0
   2.96  2.82   9.1  22.8  38.4  51.0  68.7  90.0  99.3   0.6  100.0
   2.82  2.69  12.6  30.7  49.6  63.5  80.3  95.4  99.7   0.2   99.9
   2.69  2.59  16.0  39.5  61.1  74.5  88.0  97.5  99.2   0.0   99.2
   2.59  2.50  19.2  46.4  67.8  79.4  89.3  94.8  95.6   0.0   95.6
 All hkl        7.2  17.8  28.5  36.5  47.6  65.0  98.8   0.7   99.5
 Shell Lower Upper Average      Average     Norm. Linear Square
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac
      50.00   5.38    76.9     4.5     2.0  0.985  0.062  0.071
       5.38   4.27    59.1     3.8     2.0  1.316  0.092  0.104
       4.27   3.73    51.4     3.6     2.2  1.472  0.111  0.118
       3.73   3.39    34.9     2.8     2.2  1.405  0.131  0.133
       3.39   3.15    21.6     2.4     2.2  1.128  0.172  0.165
       3.15   2.96    13.7     2.4     2.3  1.002  0.247  0.237
       2.96   2.82    10.4     2.5     2.4  0.947  0.330  0.304
       2.82   2.69     7.4     2.6     2.6  0.887  0.452  0.413
       2.69   2.59     5.5     2.9     2.9  0.868  0.605  0.559
       2.59   2.50     4.4     3.6     3.5  0.850  0.714  0.649
  All reflections     28.6     3.1     2.4  1.098  0.142  0.110
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Data collection EspB (1-292) 
     Space group P21 
     Cell dimensions  
           a, b, c (Å) 173.448,81.703,267.467 
           α, β, γ (°) 90, 108.77, 90 
     Molecules/Asym. unit   16 
     Wavelength (Å) 0.97921 
     Resolution (Å) 50-2.50 
     Rsym (last shell)  0.142 (0.452) 
     Completeness (%) 99.5 (95.6) 




   Resolution (Å) 43.8-2.50 
   Rwork/Rfree (%) 21.0/24.9 
   Mean B-factors (Å)2   
          Residues  
 49.8 
   RMSD Bond lengths (Å) 0.009 
   RMSD Bond angles (°) 1.176 
 Ramachandran Plot  
    Favored 96.3% 
    Allowed 0.0% 

















     Shell       Average Redundancy Per Shell
  Lower Upper      
  limit limit
  50.00  5.81             6.9
   5.81  4.62             6.6
   4.62  4.03             6.5
   4.03  3.66             6.3
   3.66  3.40             6.2
   3.40  3.20             6.1
   3.20  3.04             6.1
   3.04  2.91             6.1
   2.91  2.80             6.0
   2.80  2.70             6.0
  All hkl                 6.3
     Shell            I/Sigma in resolution shells:
  Lower Upper      % of of reflections with I / Sigma less than
  limit limit     0     1     2     3     5    10    20   >20  total
  50.00  5.81   0.4   0.6   0.9   1.5   2.7   7.5  72.2  27.7   99.9
   5.81  4.62   1.5   2.1   3.0   4.1   6.5  16.3 100.0   0.0  100.0
   4.62  4.03   2.7   3.4   4.4   5.6   8.6  17.3  55.7  44.3  100.0
   4.03  3.66   3.5   4.6   6.3   8.4  12.8  25.7  63.6  36.4  100.0
   3.66  3.40   4.4   6.5   9.5  12.9  19.6  37.0  70.2  29.7   99.9
   3.40  3.20   6.4  10.0  14.7  19.9  30.1  51.1  79.7  20.1   99.9
   3.20  3.04   8.5  14.9  22.8  29.8  42.2  65.0  88.4  11.3   99.7
   3.04  2.91  10.3  18.5  28.2  36.9  51.4  74.6  93.1   6.4   99.5
   2.91  2.80  12.4  22.9  34.6  45.0  59.9  81.1  95.0   4.1   99.1
   2.80  2.70  14.9  28.2  42.3  53.9  69.2  87.1  96.4   1.9   98.3
 All hkl        6.5  11.1  16.6  21.7  30.1  46.1  81.4  18.2   99.6
 Shell Lower Upper Average      Average     Norm. Linear Square
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac
      50.00   5.81   294.5    15.6     3.6  1.736  0.101  0.119
       5.81   4.62   161.9    10.0     3.3  1.559  0.115  0.127
       4.62   4.03   180.1     8.8     4.1  2.371  0.125  0.134
       4.03   3.66   128.1     6.7     4.0  2.469  0.145  0.151
       3.66   3.40    85.2     5.0     3.9  2.433  0.168  0.167
       3.40   3.20    55.4     4.2     3.8  2.086  0.203  0.189
       3.20   3.04    35.7     3.9     3.7  1.771  0.270  0.241
       3.04   2.91    27.3     3.9     3.8  1.576  0.335  0.289
       2.91   2.80    20.8     3.9     3.8  1.462  0.422  0.360
       2.80   2.70    14.9     3.9     3.8  1.292  0.548  0.463
  All reflections    101.5     6.6     3.8  1.880  0.146  0.131
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     Shell       Average Redundancy Per Shell
  Lower Upper      
  limit limit
  50.00 12.86             4.3
  12.86 10.24             4.7
  10.24  8.95             4.7
   8.95  8.14             4.5
   8.14  7.56             4.5
   7.56  7.11             4.6
   7.11  6.76             4.6
   6.76  6.46             4.6
   6.46  6.21             4.7
   6.21  6.00             4.7
  All hkl                 4.6
     Shell            I/Sigma in resolution shells:
  Lower Upper      % of of reflections with I / Sigma less than
  limit limit     0     1     2     3     5    10    20   >20  total
  50.00 12.86   2.5   2.9   2.9   3.2   4.6  44.4  97.6   0.0   97.6
  12.86 10.24   0.8   1.1   1.5   2.3   4.1  29.6 100.0   0.0  100.0
  10.24  8.95   0.7   1.6   2.8   4.1   7.2  33.7  99.7   0.0   99.7
   8.95  8.14   1.5   3.9   6.7  10.1  20.0  51.8 100.0   0.0  100.0
   8.14  7.56   1.5   5.9  12.6  18.9  32.2  57.0  99.0   1.0  100.0
   7.56  7.11   2.8   8.2  16.3  25.0  45.1  73.1  99.2   0.7   99.9
   7.11  6.76   5.8  13.8  28.7  40.4  59.9  87.0  99.9   0.1  100.0
   6.76  6.46   7.1  19.6  35.3  49.6  68.4  94.1 100.0   0.0  100.0
   6.46  6.21   7.1  21.3  38.9  55.1  75.8  95.0  99.7   0.3  100.0
   6.21  6.00   9.7  27.0  49.2  63.6  81.4  96.5 100.0   0.0  100.0
 All hkl        4.0  10.5  19.5  27.2  39.9  66.2  99.5   0.2   99.7
  Shell Lower Upper Average      Average     Norm. Linear Square
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac
      50.00  12.86    99.6    10.6     2.7  1.823  0.128  0.138
      12.86  10.24    83.9     7.1     1.7  1.763  0.130  0.144
      10.24   8.95    63.2     5.4     1.7  1.958  0.148  0.151
       8.95   8.14    32.4     2.9     1.4  2.116  0.166  0.161
       8.14   7.56    19.7     1.9     1.4  1.977  0.200  0.220
       7.56   7.11    13.1     1.6     1.4  1.726  0.257  0.264
       7.11   6.76     8.1     1.5     1.4  1.304  0.345  0.338
       6.76   6.46     6.3     1.5     1.5  1.312  0.436  0.431
       6.46   6.21     5.7     1.5     1.5  1.040  0.455  0.417
       6.21   6.00     4.6     1.6     1.6  1.146  0.601  0.550
  All reflections     33.5     3.5     1.6  1.611  0.170  0.151
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Table 6.5: EspB (1-346) Scalelog file  
 
 









     Shell       Average Redundancy Per Shell
  Lower Upper      
  limit limit
  40.00 14.34             3.6
  14.34 11.47             3.9
  11.47 10.05             4.0
  10.05  9.14             4.0
   9.14  8.49             4.1
   8.49  7.99             4.1
   7.99  7.60             4.1
   7.60  7.27             4.0
   7.27  6.99             4.0
   6.99  6.75             3.8
  All hkl                 4.0
     Shell            I/Sigma in resolution shells:
  Lower Upper      % of of reflections with I / Sigma less than
  limit limit     0     1     2     3     5    10    20   >20  total
  40.00 14.34   5.8  13.6  20.3  26.4  33.2  42.4  76.6  23.1   99.7
  14.34 11.47   5.5  17.2  28.5  33.6  46.7  62.4  81.4  18.6  100.0
  11.47 10.05  10.3  22.5  32.1  39.1  49.1  65.3  88.2  11.4   99.6
  10.05  9.14  11.8  22.9  41.2  49.6  59.9  76.3  89.7  10.3  100.0
   9.14  8.49  18.8  37.5  53.9  60.2  69.5  87.1  96.1   3.9  100.0
   8.49  7.99  13.8  38.7  53.3  64.4  75.5  88.5  95.8   4.2  100.0
   7.99  7.60  13.5  39.4  58.2  67.3  80.5  90.8  97.6   2.4  100.0
   7.60  7.27  15.6  41.6  57.2  70.4  79.2  92.4  99.6   0.0   99.6
   7.27  6.99  24.2  42.7  60.8  69.6  79.6  90.0  96.5   2.3   98.8
   6.99  6.75  15.7  41.0  58.6  67.9  80.3  94.8  96.8   0.0   96.8
 All hkl       13.3  31.2  45.8  54.1  64.6  78.2  91.5   8.0   99.5
 Shell Lower Upper Average      Average     Norm. Linear Square
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac
      40.00  14.34    19.3     1.0     0.7  1.159  0.057  0.033
      14.34  11.47    11.3     0.6     0.6  1.018  0.081  0.066
      11.47  10.05     8.7     0.6     0.5  0.974  0.089  0.055
      10.05   9.14     6.3     0.6     0.5  0.958  0.134  0.085
       9.14   8.49     2.8     0.5     0.5  0.996  0.213  0.143
       8.49   7.99     3.1     0.5     0.5  0.948  0.251  0.158
       7.99   7.60     2.4     0.5     0.5  0.709  0.263  0.172
       7.60   7.27     1.6     0.6     0.5  0.855  0.423  0.294
       7.27   6.99     1.8     0.6     0.6  0.961  0.332  0.204
       6.99   6.75     1.2     0.6     0.6  0.677  0.463  0.402
  All reflections      6.1     0.6     0.6  0.929  0.136  0.057










Figure 6.5: Overall structure of EspB (1-292). Tetramer of tetramers, two 
tetramers:  1 and 3; and 2 and 4 are parallel and adjacent tetramers interact via the C-















































Figure 6.6: Overall structure of one homotetramer. Monomer A is in magenta, 
monomer B in yellow, monomer C in blue and monomer D in green. Monomers A 
and B are anti-parallel and so are monomers C and D. Monomers A and D as well as 
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Figure 6.7: Overall monomeric structure. The monomer is mostly helical and 























































Figure 6.8: Interacting interfaces. Black dashed lines are hydrogen bonds and red 
spheres are waters. A. Interface between the C-lobe helices (α4, α5 and α6). B. 
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Chapter 7: Summary and Conclusion 
 
 
7.1 Summary  
 
  Regulating the rate of ribosome biogenesis is an accessible avenue to 
modulating cell proliferation, especially in abnormal proliferative cells such as cancer 
cells. One approach of achieving regulation of cell proliferation is by targeting 
proteins involved in ribosome biogenesis. This approach has precedence in studies 
that show deletion of a ribosomal protein, S6 in mice results in decreased cell 
proliferation yet cell growth is sustained in response to nutrient stimuli. The work 
described here takes the same approach by targeting Rio1 kinase that is required for 
both maturation of 18S rRNA during ribosome biogenesis and cell cycle progression. 
Towards this approach, potential inhibitors were tested for binding to Archaeoglobus 
fulgidus Rio1 (afRio1).  
Small molecules were selected based on a previously solved crystal structure 
of afRio1 bound to ATP/Mn2+ that revealed an accessible pocket near the N7 position 
on the adenine moiety of ATP. Toyocamycin, sangivamycin, 7-methylinosine and 
ATP/Mg2+ were tested for binding to afRio1 using a thermofluor assay. 
Toyocamycin, an adenosine analog with a carbon and a cyano group at the N7 
position demonstrated the highest affinity for afRio1. Despite the lack of a 
triphosphate moiety, toyocamycin stabilized afRio1 and bound to afRio1 with a 
higher affinity than the native ligand, ATP/Mg2+. Co-crystallization of afRio1 with 
toyocamycin resulted in a crystal structure of afRio1-toyocamycin that showed 
occupancy of toyocamycin in the ATP binding pocket. Interactions between 
toyocamycin and afRio1 revealed the metal binding residue, Asp 212 that interacts 
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the γ-phosphate of ATP via a metal-mediated interaction, was able to hydrogen bond 
with the 5’OH of toyocamyin despite the lack of a triphosphate moiety. This suggests 
that the triphosphate moiety may not be critical for tight binding to afRio1, as 
toyocamycin binds with a higher affinity to afRio1 than ATP. The presence of the 
cyano group at the N7 position on toyocamycin may also facilitate tighter binding. 
Also additional hydrogen bonds, both direct and water-mediated, that are observed in 
afRio1-toyocamycin complex but not the ATP bound structure may compensate for 
the lack of the triphosphate moiety.  
 Binding of toyocamycin to the ATP binding pocket necessitated inhibition 
studies that were carried out to validate competitive inhibition that occurs when the 
inhibitor binds to the substrate’s pocket. Competitive inhibition is characterized by a 
change in the affinity of the enzyme for the substrate (Km) and no change in the 
enzyme’s maximum catalytic rate (Vmax). AfRio1 inhibition studies revealed 
unexpected results of a change in both the Km and Vmax. Though crystallographic 
studies suggested strict competitive inhibition, steady state kinetic studies suggested 
that uncompetitive inhibition mechanism was also in play. This required assuming a 
mechanism that could account for both competitive and uncompetitive inhibition. A 
mixed inhibition model that is characterized by a change in both Km and Vmax was 
adopted in an effort to explain the results.  Mixed inhibition occurs via allosteric 
modulation where the inhibitor binds to a different site than the substrate’s binding 
pocket or through modulation of binding sites via formation of oligomers. Since co-
crystallization studies showed occupancy of toyocamycin in the ATP binding pocket, 
the only other notion to explore was the formation of oligomers. In addition to 
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inhibition of afRio1 by toyocamycin, another phenomenon known as substrate 
inhibition that occurs in the presence of multiple binding sites was observed at high 
concentrations of ATP. In order to explain both mixed inhibition and substrate 
inhibition, sedimentation equilibrium experiments were carried out to determine 
whether oligomers were being formed. In the presence of toyocamycin, a monomer-
tetramer with an average molecular weight of 71.8 kDa was observed in solution. In 
the presence of ATP, a monomer-dimer with an average molecular weight of 53.6 
kDa was observed whereas when phosphorylated afRio1 has a molecular weight of 
34.1 kDa and fits to a single species model that is monomeric. In the presence of ATP 
or toyocamycin, the monomeric afRio1 (phosphorylated afRio1) average molecular 
weight increases to 47.6 kDa and 46.2 kDa respectively and both fit to a monomer-
trimer model. Taken together this data suggests that ATP and toyocamycin promote 
oligomerization and both ligands stabilize a less catalytically active oligomer. Crystal 
packing analysis of the different oligomers revealed that ATP and toyocamycin 
stabilized the same type of dimer and have a similar interacting interface, different 
from the adenosine bound structure. This was somewhat unexpected since 
toyocamycin is an adenosine analog, and lacks the triphosphate moiety. Despite this, 
toyocamycin favors the ATP bound bound conformation and the data supported and 
was consistent with both mixed inhibition and substrate inhibition. This data also 
links autophosphorylation and oligomerization as a mechanism that afRio1 uses to 
modulate afRio1 catalytic activity. 
 There is currently no crystal structure of eukaryotic Rio1 kinase and part of 
my research was to determine the crystal structure of human Rio1 kinase, RioK1.  
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Several strategies were employed in cloning, expressing and purifying a construct of 
RioK1. This included limited proteolysis and surface entropy mutagenesis 
complemented by mass spectrometry analysis. RioK1 residues 143-494, was the most 
stable fragment and resulted in the first crystal structure of RioK1 with ATP/Mg2+ 
bound. Analysis of the interaction between RioK1 and ATP/Mg2+ revealed similar 
hydrophobic contacts and hydrogen bonds as those observed between afRio1 and 
ATP/Mn2+. An alignment of RioK1-ATP/Mg2+ with afRio1-ATP/Mn2+ had an RMSD 
of 0.894 Å over 158 residues with shifts observed on the N-lobe’s twisted β-sheet, the 
nucleotide binding loop, the hinge region and the metal binding loop. In the 
alignment, the γ-phosphate of ATP in the RioK1 (143-494)-ATP /Mg2+ is oriented 
differently compared to the afRio1-ATP/Mn2+ structure. In addition, the distance 
between the γ-phosphate and the metal binding residue is 3.3 Å in the RioK1-ATP 
complex whereas in afRio1-ATP/Mn2+ this distance is 5.1 Å. The difference in this 
distance can be attributed to the shift in the metal binding loop and is also suggestive 
of a difference in the catalytic rate activity between eukaryotic Rio1 and afRio1. 
Crystal packing analysis using PDBe PISA (protein interfaces, surface and 
assemblies) server, resulted in two potential biological interfaces, one between the 
two molecules in the asymmetric unit and another interface between two symmetry 
related molecules. Mutational studies, oligomeric characterization and functional 
studies would aid in determining the biological relevant interface.  
 In addition to structure determination of RioK1, there was interest in 
determining whether biochemical characteristics determined for afRio1 were 
conserved in RioK1. RioK1 oligomeric state characterization, affinity for potential 
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Rio1 inhibitors and substrate inhibition by high concentrations of ATP were analyzed.  
In all three cases, RioK1 showed a similar trend as afRio1, in the presence of ATP 
and adenosine, RioK1 formed a dimer and tetramer respectively and when 
phosphorylated RioK1 was a mixture of monomer-dimer in solution suggesting that 
RioK1 may employ the same inhibition mechanism as afRio1 and phosphorylation 
may regulate catalytic activity. At high concentrations of ATP above 9.0 µM, RioK1 
phosphorylation activity was inhibited, as was the case with afRio1 suggesting that 
both proteins may employ the same substrate inhibition mechanism through 
stabilization of a less catalytically active form. Finally during analysis of RioK1’s 
affinity for potential inhibitors, toyocamycin bound to RioK1 with a higher affinity 
than ATP/Mg2+. This is similar to what was observed with afRio1 suggesting that 
toyocamycin may bind and interact with RioK1 as it does with afRio1. Interestingly 
both eukaryotic and archaeal Rio1 kinase demonstrate conservation in both structural 
features and biochemical characteristics despite over a billion years of evolution.  
 In addition to studying Rio1 kinase, this thesis presents the first crystal 
structure of a mycobacterium tuberculosis virulent factor known as EspB. The EspB 
(1-292) structure shows a conserved arrangement of tetramers at different pH 
conditions and in different crystal forms. The crystal structure of a larger fragment, 
EspB (1-346), also shows the same arrangement of tetramers suggesting that the 
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7.2 Future Work and Direction 
 Co-crystallization studies of afRio1 with toyocamycin provide a first 
generation class of inhibitors that will aid in designing more Rio1-specific inhibitors. 
This would include: a) exploring different substitution groups at the N7 position as 
well as the base b) exploring substitution on the ribose, for instance on the 3’OH that 
has the closest residue 6.2Å away, c) functionalizing the triphosphate moiety by 
introducing non-hydroylzable groups (NH2, S, CH) between the β and γ phosphates 
or d) molecules that mimic the transition state. Identifying Rio1 substrates is also key 
in determining Rio1-specific peptide inhibitors, a tool that has been used to determine 
kinase inhibitors. An example of a kinase peptide inhibitor is Kemptide that inhibits 
Protein Kinase A (PKA).  These studies would also require characterizing the mode 
of inhibition. 
A co-crystal structure of the human Rio1 (RioK1) with toyocamycin bound 
would aid in determining whether toyocamycin maintains similar interactions with 
RioK1 as with afRio1. In addition to crystallization, inhibition studies would be 
essential to determine both afRio1 and RioK1 share the same inhibition mechanism. 
This would be beneficial in designing Rio1-specific inhibitors since those that inhibit 
afRio1 would possibly inhibit RioK1. This would also serve as a valuable tool in 
identifying Rio1 substrates by using radiolabeled toyocamycin triphosphate or by 
identifying proteins with diminished phosphorylation activity in he cells in the 
presence of toyocamycin. Both methods have been explained explicitly in chapter 2.   
Recent studies that have identified an interaction of RioK1 with protein arginine 
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methyltransferase 5 and nucleolin provide the opportunity to study the crystal 
structures of the complexes and better characterize the interaction.  
 In addition to Rio1 studies, work done with EspB requires determination of 
EspB oligomeric states in the presence of different conditions that mimic phagosomal 
environment, the crystal structures of proteolytic fragments of EspB as a result of 
cleavage of Myc1 after secretion from the cytoplasm as well as determining the role 
of these fragments. The crystal structure of EspB bound to ESAT-6, the ATPase 
Rv3871 and Myc1 protease would be also be essential in better understanding the 
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